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ABSTRACT 
 Physical activity can prevent cardiovascular disease, obesity, type II diabetes and some 
types of cancer.  With only 3.5% of adults meeting the recommended physical activity 
guidelines, research has focused on the regulatory factors that influence physical activity level.  
Genetic influence accounts for the majority of physical activity regulation.  However, there is 
limited information on the mechanisms that affect physical activity, in part, because of a lack of 
reliable methods to silence genes in vivo.  The purpose of this dissertation was to identify 
mechanisms in skeletal muscle that influence physical activity. The methods used to accomplish 
the purpose of this dissertation were the evaluation of Vivo-morpholinos as a gene silencing 
tool in skeletal muscle and brain, identification of proteins in skeletal muscle associated with 
increased physical activity level, and the use Vivo-morpholinos to transiently knockdown the 
identified skeletal muscle proteins as a means to elucidate mechanisms for the peripheral 
regulation of physical activity.  Overall, this study showed that Vivo-morpholinos effectively 
silenced genes in skeletal muscle yet required the use of a pharmacological aid to achieve gene 
silencing in the brain.  Additionally proteins associated with calcium regulation (Annexin A6 and 
Calsequestrin 1) and the Kreb’s (TCA) cycle were found to be over expressed in the high active 
animals.  The knockdown of Annexin A6 and Calsequestrin 1 resulted in a significant decrease in 
physical activity, thus showing that calcium regulation could influence the physical activity 
response.  While these results provide a potential mechanism for the peripheral regulation of 
physical activity, a side effect observed was that Vivo-morpholinos can hybridize resulting in 
increased mortality rates of the treatment animals.  Therefore, we developed methods to 
alleviate the toxic effects of Vivo-morpholinos.  Thus, this dissertation refined a technique for 
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determining a gene’s effect in an in vivo model and identified two candidate proteins (Annexin 
A6 and Calsequestrin 1) that play a role in regulating daily physical activity.    
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NOMENCLATURE 
Mouse Gene Italicized First Letter Capitalized (ex: Glut4) 
Human Gene ALL CAPITALIZED ITALICIZED (ex: GLUT4) 
Mouse Protein  First Letter Capitalized (ex: Glut4)  
Human Protein ALL CAPITALIZED (ex: GLUT4) 
The literature has used “over expression,” “over-expression,” and “overexpression” to 
characterize the increase in gene/protein amount.  For this dissertation “over expression” will 
be used.  
Figures are presented in the appendix and denoted by the section they are referenced in 
followed by the figure number (i.e. 2.3 represents figure 3 in section 2) 
All tables in this dissertation are referenced in section 3.  The tables are presented in the 
appendix. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Behavior traits, such as voluntary physical activity, are generally accepted to be a result 
of environmental and genetic/biological factors.  A large amount of literature1-4 has examined 
the environmental influence on physical activity.  While the literature has focused on 
environmental factors such as culture, peer influence, and the “built environment” (i.e. access 
to sidewalks)2-4, it has been shown that the main effects contributing to the control of voluntary 
physical activity are genetic and biological influence5.  Voluntary physical activity is an 
important trait to study because it has been positively correlated with decreases in 
cardiovascular disease, obesity, type II diabetes and some types of cancer5.  With only 3.5% of 
adults meeting the recommended physical activity guidelines6, physical inactivity is the second 
actual leading cause of death (~250,000 cases/year) in the United States7, with an estimated 
$507 billion a year in health care costs8.  Thus, the identification of mechanisms that regulate 
voluntary physical activity could improve the quality of life of individuals and potentially reduce 
health care costs.  Despite promising research on the genetic regulation of physical activity, 
there has been limited information on mechanisms that regulate physical activity.   
While the literature has not provided specific mechanisms for the regulation of physical 
activity, the literature has provided models by which to study physical activity that could be 
used to identify mechanisms associated with voluntary physical activity.  Two of the most 
widely used models for voluntary physical activity regulation are humans9,10 and mice11-17.  
Human studies require a large number of subjects in order to achieve statistical power to 
elucidate the genetic regulation of physical activity due to the heterozygous nature of the 
1
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human genome10.  A method to reduce the heterozygous nature of the human genome is the 
use of identical twins as subjects10.  This technique has been employed with some success in 
the physical activity literature, which has shown genetic influence accounting for 48-71% of the 
effect on physical activity level10.  However, a limitation on virtually all of the human activity 
literature is that the method used was a survey, where subjects were asked to recall their past 
physical activity levels10.  While a popular tool, the use of recall surveys could skew the results 
due to the subjective nature of data collection5; for example,  recall surveys have estimated 
that the number of Americans that meet the physical activity requirements for health benefits 
ranges from 7-70% which is widely variant from the 3.5% measurement derived from objective 
measurements18.  The discrepancy in the survey data is a result of the type of questions used to 
classify physical activity, with most agreeing that in order to assess physical activity level, 
questions must address physical activity intensity, frequency, and duration18.  Physical activity 
intensity is objectively measured by the amount of energy expended during a bout of activity 
(expressed as kilojoules); however, most questionnaires do not reliably address physical activity 
intensity due to the fact that most often the questions are presented in a way where the 
subject must provide a subjective rating ranging from “easy” to “hard”18.   Frequency is the 
number of activity bouts a subject partakes in during a defined time span and often frequency 
is over estimated by recall surveys especially if the survey requires the subject to recall a time 
period longer than three months18.  Alternately, short term surveys have not been found to be 
more reliable than long term surveys due to the fact that surveys that measure only one week 
often do not distinguish between weekday and weekend, which depending on the subject’s 
occupation can reflect drastically different physical activity levels18.  Lastly, the evaluation of 
duration (time spent doing activity) is problematic for recall surveys in that subjects report the 
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time allotted for physical activity and not the amount of time engaged in physical activity18.  
This phenomenon is often observed in children’s gymnasium classes where physical activity is 
reported on a survey as the duration of the class period but in fact the majority of that time the 
child is listening to the instructor or waiting his/her turn to engage in physical activity18.  Thus, 
physical activity level is over estimated by surveys and can potentially skew results associated 
with the phenotype.  
Another approach to examining genetic mechanisms of physical activity is to use animal 
models, which have several benefits over the human model.  Specifically, mice can be bred to 
limit heterozygosity of the population, environmental factors can be controlled by the 
investigator, and the short life span of the animal provides the opportunity to measure physical 
activity across multiple generations5.  Inbred mice are produced using at least 20 consecutive 
generations of parent x offspring or sister x brother mating, allowing for mice to be genetically 
homozygous at all loci12.  Thus, the use of inbred mice allow for the rigorous control of 
heterozygosity of the genome and the environment allowing for controlled investigation into 
the genetic regulation of physical activity.  Furthermore, the mouse is an excellent model of the 
human genome given that there is approximately 75% homology between the mouse and 
human genome19.  While there is some discrepancy in homology between mice and humans, 
this difference appears to be a result of differences in non-coding regions of the genome19.   
Thus, the demonstrated human-mouse genomic homology increases the probability that 
results from genetic studies using the mouse model can be directly translated to humans.  
 To evaluate voluntary physical activity in the mouse model several methods have been 
utilized.  The most frequently used methods in the literature have been wheel running, home 
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cage activity, and maze activity.  However, it has been suggested that studies using home cage 
activity and/or maze activity evaluate both physical activity level and fear/ anxiety level20.  
Therefore, results from cage and maze activity studies may provide ambiguous results since this 
methodology characterizes both physical activity level and fear/anxiety.  Therefore, in the 
mouse model, the method most often used to assess voluntary physical activity level is wheel 
running12.  Wheel running as a measure of physical activity has a similar physiological response 
as does partaking in physical activity by humans, such as self-selection of intensity, heart rate 
response, and neurological changes.  Specifically it has been shown that humans self select an 
average running intensity of 70%21.  Interestingly it has been shown that mice self select a 
wheel running intensity of 65-70%22. The self-selection of physical activity level results in similar 
cardiovascular and neurological adaptations between mice and humans.  Adlam et al23 showed 
that during wheel running there was a significant increase in heart rate and blood pressure, 
however following five weeks of wheel running there was a decrease in resting heart rate and 
blood pressure23.  Similarly, the human literature has shown that regular bouts of moderate 
intensity exercise (60-70% max heart rate) result in a decrease of resting heart rate and systolic 
blood pressure24,25.  Additionally, mouse wheel running and human physical activity 
engagement result in similar neurological responses.  Dishman et al26 characterized the 
norepinephrine, 5-hydroxytryptamine, dopamine, and gamma aminobutyric acid responses to 
wheel running and showed that there was an increase in norepinephrine and dopamine 
following mouse wheel running which led the authors to conclude that physical activity had a 
protective effect on brain monoamine depletion and thus an antidepressant affect26.  The 
human literature has documented similar findings of antidepressant effects following bouts of 
physical activity27.   However, due to the nature of the study, brain monoamines could not be 
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directly measured in humans26 for comparison to the mouse model.  Given the similarities 
between human and mouse physiological parameters during voluntary exercise and voluntary 
wheel running, the use of the mouse wheel running model is appropriate to determine the 
regulation of physical activity level with the use of genetic linkage, transcriptome, and 
proteome analyses. 
1.1 Genomic Regions Associated with the Regulation of Voluntary Physical Activity 
 As noted earlier, it has been shown that in the mouse and human model an individual’s 
genome influences physical activity level5,13.  Most often, the genetic influence on a trait is 
characterized as heritability (i.e. how much parental lineage affects behavior of the individual).  
Heritability is most often expressed as a percentage of the total phenotype28.  The human 
literature has shown that genetic regulation accounts for 20-92% of the influence on voluntary 
physical activity level5,9,10.  The large range in genetic influence could be due to the 
methodology used to evaluate the physical activity phenotype.  When using accelerometers 
Joosen et al9 found genetic influence accounted for 92% of physical activity regulation9.  
However, Stubbe et al10 used 37,051 twin pairs and observed that the genetic influence on 
physical activity level ranged from 48-71% with nationality being one of the largest factors 
accounting for the variance10.  The Stubbe study used self-reported surveys on leisure time 
activity to assess physical activity level10.  The different methodologies from the Joosen 
(accelerometer) and Stubbe (survey) studies could account for the difference in heritability, in 
that it has been shown that recall surveys do not correlate with actual physical activity level18.  
As to the ‘nationality’ component in the Stubbe study it was demonstrated that cultural 
background also influenced heritability, specifically subjects from Australia, the Netherlands, 
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and Norway had higher heritability associated with physical activity as opposed to subjects 
from Sweden and Demark10; this is not surprising in that it has been shown that cold weather 
climates decrease the physical activity response due to individuals remaining indoors18. The fact 
that Norway and the Netherlands (both cold weather climates) had higher heritability 
associated with physical activity is a result their culture endorsing outdoor activity10.  Thus, the 
influence of the environment on activity lends support for the mouse model because the 
investigator can directly and robustly control the environmental influence5.   In the adult mouse 
model directly measuring wheel running resulted in a heritable range of 50-80% for the 
regulation of physical activity level29.  Thus, heritability studies using both the human and 
mouse model have shown a heritable range of 20-92%, with the majority of work centering on 
50-70% influence on physical activity.  Building on the results of the heritability studies, 
research has focused on identifying genetic mechanisms associated with physical activity.    
 Studies seeking to understand the genetic architecture of high and low active subjects 
have used a variety of approaches, with most employing either a positional cloning or linkage 
analysis approach30.  In either approach, one of the early steps is to determine quantitative trait 
loci (QTL) which identifies regions of the genome that are correlated to voluntary physical 
activity.  Lightfoot et al13 was the first to determine QTL for mouse wheel running and used 
time spent on the wheel (duration), distance run on the wheel and the speed that the mouse 
ran on the wheel as the three phenotypes13.  In order to accomplish this, the authors crossed 
high active inbred C57L/J mice with low active inbred C3H/HeJ mice and bred these mice to the 
F2 generation.  The authors showed that an area on chromosome 13 was associated with 
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increased wheel running time, distance, and speed.  Additionally a region on chromosome 9 
was associated with wheel running speed13.  
 From these results, Yang et al17 aimed to explore the role of chromosome 13 on 
voluntary physical activity using a chromosome substation mouse model whereby chromosome 
13 from the low active A/J mice was substituted into the high active C57Bl/6J (B6) mouse.  The 
results showed that the B6 group had a significantly higher physical activity level than both the 
low-active A/J mice and the B6 mice with chromosome 13 from the low active A/J mice17.  As a 
follow-up, Yang et al16 backcrossed the chromosome 13 substitution mice with the high active 
B6 mice to provide high resolution mapping for voluntary physical activity.  Yang et al16 selected 
15 single nucleotide polymorphism (SNP) markers on chromosome 13 for analysis in an attempt 
to identify genes associated with physical activity16.  The results showed that two genes, 
dopamine receptor 1 (Drd1) and transcription factor AP-2 alpha (tcfap2a), were associated with 
voluntary physical activity level.  Additionally, the finding by Yang et al16 of tcfap2a involvement 
further supports the role of Drd1 because tcfap2a is a transcription factor for Drd1 and can 
increase Drd1 expression16.  Thus, Yang and colleagues’ data, even though correlative, 
suggested that dopamine acted to influence motivation and reward driven behavior, which in 
the case of physical activity, can “drive” the voluntary physical activity response.  
   While the work by Yang and Lightfoot is promising, the basis of the experimental design 
to examine chromosome 13 was centered on the comparison of only two inbred mouse strains 
(C57L/J and C3H/HeJ) from Lightfoot et al13.  To further elucidate the genetic regions associated 
with physical activity, Lightfoot et al12 increased the number of inbred mouse strains analyzed 
from two to 41 strains.  In these 41 strains, the authors also included wild type strains to help 
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offset the “bind spots” of identical genomic regions from descent of inbred mouse strains12.  
Not only did these results characterize the wheel running phenotype for these strains but 
identified several additional genomic regions associated with physical activity as well as the 
influence of sex on activity.  Specifically, distance run was associated with genomic regions on 
chromosome 12, 18, and 19; however, when only analyzing males, distance run was associated 
with regions on chromosome 5, 6, 8, and 13.  The females had regions associated with distance 
run on chromosome 8 and 11.  Additionally when excluding the wild type mice there was a 
region on chromosome X associated with time spent running by the females12.   
 Another approach to determining the genetics of physical activity is through selective 
breeding of mice that are high active, i.e. the generation of an inbred strain whose primary 
characteristic is high activity.  Garland’s lab selected mice that displayed high wheel running 
(9,000 revolutions per day) and have bred the mice to the 65th generation14 31.  One of a 
number of interesting observations in these mice displayed the “mini-muscle” phenotype32.  
The mini muscle is primarily characterized by a reduction in size of the triceps surae muscle of 
high active mice.  Interestingly this phenotype has been associated with increased aerobic 
capacity, muscle contractile performance, size of heart ventricles, size of liver, and size of 
spleen14.  In 2008, Hartmann et al14 mapped the mini muscle phenotype to chromosome 11 
within the 2.6335 Mbp region14.  However, this region of chromosome 11 contains 102 genes14.  
Thus, the high number of genes located in the region on chromosome 11 prevents the 
determination of the genetic mechanisms associated with the mini muscle and the regulation 
of voluntary physical activity.  
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 In an effort to understand which regions were associated with voluntary physical 
activity aside from just the mini-muscle phenotype, Nehrenberg et al 201033 QTL mapped the 
selective-bred high active mice for the phenotypic components of physical activity (e.g. daily 
distance run, etc.).  The results showed that the regions associated with average speed of 
wheel running were located on chromosome 7, max speed of wheel running was located on 
chromosomes 6 and 7,  ventricle size was located on chromosome 3, and spleen size was 
located on chromosome 6, 9 and 1333.  Interestingly the authors found that average speed and 
max speed were associated with the tyrosinase gene33 (a precursor to dopamine) which was 
associated with physical activity as shown by Yang et al’s QTL study16.  However, and perhaps 
due to different founder animals for the selective breeding as compared to previous QTL 
studies, none of the QTL identified by Nehrenberg, et al. co-localized with QTL identified by 
Lightfoot, et al12,13. 
 In an effort to develop a finer mapping analysis of the mini muscle and physical activity 
phenotype, especially in regards to the role of tyrosinase and dopamine, Kelly et al 201034 
crossed the “mini-muscle” mice with the B6 mouse34.  The authors supported the earlier study 
by Hartmann et al14  that found that the mini muscle was associated with chromosome 11 and 
tyrosinase.  However, Kelly and colleagues also found that the QTL for running distance 
appeared to change across time and was affected by exposure of the mouse to the running 
wheel34.  The finding that the QTL associated with activity changed on a daily basis was 
subsequently supported by Leamy et al35 using the earlier data from Lightfoot et al12.  
The fact that the QTL for wheel running distance might change on a daily basis 
highlights a significant limitation of QTL analysis, as well as both positional cloning and linkage 
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analysis techniques: they do not provide mechanistic pathways for the regulation of the desired 
phenotype, merely correlative evidence.  If the phenotype slightly changes – as was the case in 
both Kelly et al34 and Leamy et al35, the correlations are altered, thus pointing to different 
genomic areas.  Therefore, in order to understand the biological regulation of physical activity, 
other portions of central genetic pathways, such as the transcriptome and the proteome, must 
be analyzed.   
While both the transcriptome and the proteome can be determined, the need to 
preferentially analyze the proteome arises from observations that transcript data (mRNA) does 
not always correlate to protein function and end phenotype36-38.  Using liver cells, Anderson and 
Seilhamer found a positive, yet weak, correlation (R2 = 0.48) between mRNA and protein 
levels38.  Furthermore Gygi et al36 using a yeast model found a 20-fold difference between 
mRNA levels and the corresponding protein levels36.  In fact, Greenbaum et al37 used RNA 
sequencing and 2D-DIGE to correlate RNA expression to protein expression.  The authors 
showed a correlation of r=0.66 for nuclear RNA to protein expression and a correlation of 
r=0.42 for mitochondrial RNA to protein expression39.  Furthermore using the inbred mouse 
model Ghazalpour et al40 demonstrated a correlation of r=0.27 between mRNA and protein 
levels40.  Ghazalpour et al40 hypothesize that the weak correlation could be a result of 
alternative splicing of the mRNA40.  Thus, while both transcriptome and proteome data would 
augment the existing QTL data regarding the genetic mechanisms regulating physical activity, 
determining the differential proteomic signatures of high- and low-active animals would 
provide a description of the molecular processes closest to the determination of the 
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phenotype.  However, if the proteome is pursued, the first concern is the site of regulation so 
that the proteome can be determined in the appropriate physiological location.   
The physiological site of activity regulation is an evolving question.  It has been 
proposed by Kelly et al34 that the genetic control of voluntary physical activity is a result of both 
central drive and peripheral capability34.  Central drive is the result of mechanisms in the brain 
that influence the “drive” to be active while the “capability” to be active is a result of peripheral 
factors that reduce pain/fatigue allowing for more sustained physical activity level41.  As 
indicated by earlier discussion, a logical starting point to address differences in mechanisms 
associated with central drive and peripheral capability is with the candidate genes identified by 
QTL analysis, specifically the role of dopamine as a means of central drive and motivation to be 
active.    
1.2 Central Drive and Reward Driven Behavior Regulate Voluntary Physical Activity 
There have been several candidate genes suggested to be involved in the central drive 
to be active which include Insig2, BC014805, Socs2, Mod1, IL-15α, Prcp, Arrdc4,and DBY15. 
However, the literature has suggested that the strongest candidate genes are those in the 
Dopamine system5.  Dopamine is responsible for reward driven behavior and as stated 
previously, has been suggested by Yang et al16 to affect the “drive” to be physically active16,42,43.  
Knab et al43 showed that high active mice under expressed dopamine receptor 1 (Drd1) and 
tyrosine hydroxylase (TH)43.  Knab’s work correlates to work by Mathes et al42 who effectively 
showed that high active mice had a decrease in dopamine receptors but an increase in 
dopamine level42, indicating high active mice have a decreased dopamine turnover rate42.  
Additionally, Mathes et al42 found that dopamine turnover was independent of wheel running, 
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which suggests that dopamine levels are inherent traits that could regulate physical activity42.  
The involvement of dopamine in the regulation of physical activity was also supported through 
pharmacological studies.  Knab et al44 was able to decrease wheel running of high active mice 
with a D1 type receptor agonist and increase activity of the low active mice with a dopamine 
transporter inhibitor44, thus effectively demonstrating that modulation of the dopamine system 
affects reward driven behavior and is a regulator of voluntary physical activity. 
 An additional component of the dopamine system that may also be involved in the 
regulation of physical activity is Vesicular monoamine transporter 2 (Vmat2).  Vmat2 stores 
dopamine in synaptic vesicles prior to the release of dopamine into the synaptic cleft and 
alterations to Vmat2 have been shown to lead to Parkinson’s Disease45.  Taylor et al45 has 
proposed two mechanisms by which a higher expression of Vmat2 is associated with higher 
activity levels45,46.  The first mechanism by which higher expression of Vmat2 increase physical 
activity is that an increased level of Vmat2 decreases free dopamine45.  Free circulating 
dopamine has been shown to have toxic effects and could reduce the effects of dopamine on 
reward driven behavior45.  The second mechanism by which Vmat2 may increase activity is that 
the higher abundance of Vmat2 allows for greater release of dopamine, which has been shown, 
by Knab and Mathes to increase physical activity42,43,45.  These findings suggest that alterations 
in dopamine levels mediated by Vmat2 contribute to the reward driven behavior that leads to 
changes in physical activity. 
 Recent literature has also suggested that the reward driven behavior of the dopamine 
system is influenced by the cannabinoid system and specifically, the cannabinoid receptor47,48.  
This hypothesis supports and augments previous work investigating the dopamine system.  
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Specifically, it has been suggested that as the cannabinoid receptor is activated, dopamine 
release is stimulated47.  Current literature47 has suggested that this response is the physiological 
mechanism for “the runners high.” Raichlen et al47 investigated this mechanism by exposing 
humans, dogs, and ferrets to moderate and high intensity exercise on treadmills and then 
collected blood samples to analyze the cannabinoid receptors’ endogenous ligands response47.  
The results showed that thirty minutes of high intensity exercise led to an increase in the 
ligands for  the cannabinoid receptors and suggested the presence of the runners high47.  
Raichlen et al47 defined the runners high as a sensation of pleasure with a coincident 
reduction in pain47.  Thus, it is possible that subjects that express a higher number of 
cannabinoid receptors could participate in longer physical activity bouts because of the 
reduction in pain and increased sense of euphoria.  This hypothesis was tested by Dubreucq et 
al48 by measuring wheel running in cannabinoid receptor 1 (CB1) knockout mice and control 
mice.  The results showed that the CB1 knockout mice ran significantly less than the control 
animals48.   
In conclusion, it has been hypothesized that there are central pathways that influence 
physical activity and current literature5,16,43,44,49 suggest that dopaminergic systems and/or 
endocannabinoid systems play a role in the drive to be active.  Most prominently, these 
systems are thought to play a role in producing increased physical activity through either 
activity-induced euphoria and/or an inhibition of pain.  While the dopaminergic and 
endocannabinoid systems are centrally located, their effects can be peripherally related since 
pain associated with activity has been correlated to skeletal muscle fatigue50.  Thus, it is 
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possible that the fatigability of skeletal muscle – a peripheral factor influencing capability - 
could also influence physical activity level.    
1.3 Peripheral Factors Affecting the Capability to be Physically Active 
 As noted earlier, Kelly, et al34 suggested that there are both central (drive) and 
peripheral (capability) mechanisms involved in regulating activity.  As shown above, there are a 
growing number of studies that have investigated potential central mechanisms.  However, 
there is limited literature addressing the role of potential peripheral “capability to be active” 
factors in regulating physical activity.  The available studies in this area have focused on skeletal 
muscle with potential peripheral factors that may be associated with physical activity 
regulation being components of substrate utilization and skeletal muscle contraction.  
1.3.1 Substrate Utilization Influences Physical Activity 
Tsao et al51 showed that an over expression of glucose transport 4 (Glut4) in skeletal 
muscle led to a fourfold increase in wheel running as compared to control animals51.  The 
methodology used by Tsao et al52 utilized an over expression of Glut4 in the 129/SV mouse 
strain52.  Specifically, the MLCl promoter was spliced upstream of the Glut4 gene allowing for an 
over expression of Glut4 in muscle and heart tissue52.  Tsao et al51 examined glucose and fat 
metabolism with Glut4 over expression and interestingly, the authors observed a 45% 
increased in food intake and a fourfold increase in wheel running as compared to the control 
mice (~1 km ran for control mice and ~4 km ran for Glut4 over expressed mice)51.  The authors 
hypothesized that glucose transport was the rate-limiting step in skeletal muscle glucose 
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uptake.  Therefore, an increase in glucose transporters could increase glucose uptake allowing 
for an increased physical activity response51.   
In addition to Glut4, there have been several studies that have shown nutritional 
factors may alter physical activity through alteration of substrate utilization.  Researchers from 
the Garland lab have shown that mice bred for high activity for over 60 generations – mice 
whose activity had plateaued at ≈ generation 25 - when treated with a high fat diet, 
significantly increased their daily wheel running by 160%53.  To date, this is the only treatment 
that Garland’s research group has used that has increased physical activity level of their high 
active mice53,54.  The fact that an increase in fat in the diet would lead to an increased activity is 
supported by the literature because high endurance athletes utilize lipids as their primary fuel 
source during activity due to the increased source of calories that fat represents53.  Therefore, 
Meek et al53 has suggested  that treatment of a high fat diet allowed for increased fat utilization 
as a primary fuel source allowing for an increased capability resulting in a higher physical 
activity level in these mice whose activity had previously plateaued53.    
1.3.2 Skeletal Muscle Force of Contraction and Muscle Fatigue Influences Physical Activity 
 The ability of skeletal muscle to produce force and recover from fatigue is another 
component that may affect physical activity.  Reichart et al55 demonstrated that an over 
expression of Drd1 in skeletal muscle increased the second messenger cAMP and increased 
skeletal muscle force production and prevented muscle atrophy55.  Thus, the ability of skeletal 
muscle to produce increased force may lead to an increased physical activity level through an 
increased capability.   
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 Calcium is a key regulator in muscle contraction56.  During muscle contraction, the axon 
terminal of a motor neuron releases a neutransmitter into the synaptic cleft.  The 
neutransmitters bind to receptors on the sarcolemma, which transmit an action potential to 
the Transverse tubule (T tubule) of the sarcolemma.  Once the action potential reaches the T 
tubule, there is a release of calcium (Ca2+) from the sarcoplasmic reticulum (SR).  Ca2+ binds to 
troponin C which causes a conformational change in tropomyosin thereby exposing actin 
binding sites allowing for binding of the myosin head25.   It is the binding of actin and myosin 
that causes skeletal muscle contraction25.  As Ca2+ is a regulator of skeletal muscle contraction it 
is foreseeable that regulators of Ca2+ homeostasis could be involved in the regulation of 
voluntary physical activity.  While there are multiple potential calcium regulator proteins that 
could be involved in physical activity regulation, because of their unique properties, we have 
chosen to concentrate on Annexin A6 and Calsequestrin 1. 
 The Annexin family of proteins, which consists of 17 different proteins in animals, is 
involved primarily in Ca2+ homeostasis57.  Annexins are expressed in all tissues and share 
structural and functional similarities with other members of the Annexin family, with the 
exception of Annexin A6 which contains a repeat sequence resulting in eight domains as 
opposed to the standard four58.   The combination of the similarities in structure and the 
expression in various tissues has led to difficulty in identifying the functions of individual 
members of the Annexin family59.  In fact, functions of Annexin A6 have been hypothesized to 
include inhibition of blood coagulation, inhibition of protein kinase C,  intracellular trafficking of 
endosomal vesicles, regulation of voltage gated calcium cannels, structural modification of 
actin, and organization of lipid components of cell membranes 57,59,60.   The function of Annexin 
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A6 in muscle is still ambiguous partly because the role of Annexin A6 varies depending on the 
type of muscle.  What is known is that Annexin A6 binds acidic phospholipids of membranes in 
a Ca2+  dependent manner
57-67.  Thus, the more calcium that is present the more binding there is 
of Annexin A6 to lipid membranes.   
 The function of Annexin A6 in smooth muscle is clearly understood thanks to the work 
of Babiychuk and colleagues61-63.  Smooth muscle contracts in a segmental pattern unlike 
skeletal and cardiac muscle and is most prominent in the gut and vasculature system where the 
muscle surrounds a lumen and is used to propel substances along the length of the lumen25.  
Babiychuk et al62 hypothesized that during smooth muscle contraction there would be stress 
placed on the cell membrane of the smooth muscle and that this stress could disrupt structures 
present in the membrane61-63.  Babiychuk et al62 showed that during relaxation Annexin A6 was 
located in the cytosol and at the initial phase of contraction, Ca2+   rose to a concentration of 
700 nM causing Annexin 2 to link micro domains of the cell membrane and sarcolemma.  This 
linking caused a further release of Ca2+  and raised  Ca
2+ 
  concentration to 800 nM, which caused 
Annexin A6 to link to the sarcolemma.  The linking of Annexin A6 to the sarcolemma allowed 
for the maintenance of force transduction while preventing cell structure damage from muscle 
contraction61-63. 
In cardiac and skeletal muscle, Annexin A6 is located around the myofibril and is 
associated with the sarcoplasmic reticulum (SR)60,64.  Song et al67 observed that in patients with 
end stage heart failure Annexin A6 was down regulated as compared to healthy age matched 
controls57,67 leading to an initial thought that the loss of Annexin A6 is what led to end stage 
heart failure.  However, Kaetzel et al58 observed that when Annexin A6 is removed from cardiac 
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muscle there is an increase in free Ca2+  which leads to an increase in the inotropic state of the 
heart thereby allowing for a mechanism to compensate for the increased work load associated 
with end stage heart failure58.  However, this does not mean that over expressing Annexin A6 
will result in a healthy heart.  Gunteski-Hamblin et al64 over expressed Annexin A6 tenfold in 
mice and observed myocyte necrosis, inflammation, and cardiac death64, which was possibly 
due to two factors: 1) a tenfold over expression of Annexin A6 is considered supraphysiological 
and not to be relevant to normal physiological function; and 2)  potential confounding with the 
method in which Annexin A6 over expression was generated.  Using cloned cDNA, Annexin A6 
was spliced into the promoter region.  However, this region also contained the promoter for 
myosin heavy chain and the authors acknowledged that this over expression methodology 
could have disrupted the myosin heavy chain promoter causing the observed cardiac death64. 
 The function of Annexin A6 in skeletal muscle is less studied as compared to cardiac 
and smooth muscle.  Initially it was shown by Diaz-Munoz et al60 that Annexin A6 bound 
calcium channels allowing for an increase in Ca2+  release
60.  Additionally, Hazarika et al68 
demonstrated that in skeletal muscle Annexin A6 is associated with the SR and that during the 
initial phase of muscle contraction with the release of Ca2+   from channels of the sarcolemma, 
Annexin A6 binds to the T tubule and propagates the further release of Ca2+ 68.  Thus, Hazarika 
et al68 proposed that Annexin A6 acts to stimulate more Ca2+   release from the SR hence 
increasing force of contraction68.  Similar to Reichart et al55’s study examining Drd1 expression 
in skeletal muscle, an increase in force production can lead to an increase in physical activity 
level55.  Therefore, Annexin A6 levels are an attractive potential mechanism for the regulation 
of voluntary physical activity level.    
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 Another regulator of calcium homeostasis in skeletal muscle that may be involved in 
regulation of physical activity is Calsequestrin 1 (Casq1).  Unlike Annexin A6, Casq1 has been 
widely investigated for its function in skeletal muscle56,69.  Casq1 is a Ca2+ buffer that helps to 
regulate the release of and reuptake of Ca2+ in skeletal muscle70.  Casq1 has a highly acidic C-
terminal tail with a high binding affinity for Ca2+.  As Ca2+ binds to Casq1 a conformational 
change in the structure occurs allowing for increased Ca2+ binding56.   It was initially thought 
that Casq1’s only function was to remove Ca2+ from the myoplasm following muscle 
contraction; however, recent evidence has shown that Casq1 functions in the release of Ca2+ 
from the Ryanodine Receptor (RyR)70.  It has been suggested that Casq1 acts on the RyR to 
inhibit Ca2+ release through triadin and junction56.  As a result of these functions, Casq1 acts as 
a Ca2+ sensor ensuring that Ca2+ levels are appropriately maintained in the muscle cell.  
Interestingly it has been noted that Casq1 knockout mice can still maintain normal muscle 
contraction in spite of their lack of Casq1.  However, the Casq1 knockout mice have increased 
lethargy, atrophy, and a decreased life span as compared to wild-type mice70. 
 There have been no studies looking at Casq1 and its relation to voluntary physical 
activity level.  However, there have been several studies that evaluated Casq1 expression 
following regular bouts of exercise71-73.  The studies by Jiao et al 71 and Sugizaki et al 73 were 
conducted in cardiac tissue and showed that with an increase in endurance training there was 
an increase in Casq1 expression71,73 suggesting that Casq1 may play a role in the increased 
endurance.  Kinnunen et al72 examined Casq1 expression in various skeletal muscle tissues 
following endurance or sprint training in a mouse model72.  Interestingly, the authors observed 
that depending on the muscle fiber composition and the type of training there was a 
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differential expression of Casq172.  Specifically it was observed that following endurance 
training there was a decrease in Casq1 in the soleus (slow twitch fiber) while there was an 
increase in Casq1 in the EDL (fast twitch fiber)72.  Following sprint training, Casq1 was increased 
in the gastrocnemius (mixed muscle fiber) and the EDL, with no change in the soleus72.  The 
authors note that in fast fiber type muscle the Ca2+  storage capacity is 3-4 times higher and the 
release of and uptake of Ca2+ is more efficient compared to slow twitch fibers72.  Thus, the 
authors propose that modulation to Casq1 following training allows for skeletal muscle to have 
increased capability to engage in the trained activity72.  Thereby, Casq1 would be an attractive 
potential mechanism to regulate physical activity through its influence on Ca2+ homeostasis.  
Combined, the above referenced studies have provided tentative evidence that 
substrate utilization and skeletal muscle contractile performance may be peripheral factors that 
directly affect the capability to be active.  However, as was the case with the QTL findings, 
these conclusions have been primarily based on correlative results highlighting the need for 
cause-effect research designs to provide mechanisms of activity regulation.  Further, as noted 
earlier, in order to understand the regulation of physical activity level an initial step would be to 
determine the proteome associated with physical activity level.  
1.4 Methods to Elucidate the Proteome that is Associated with Voluntary Physical Activity 
 There are several methods to measure protein differences.  The most well established 
method is by using western blots, which can provide semi-quantitative measurements of a 
known protein.  However, identification of differential expression of multiple unknown proteins 
requires methodologies other than western blotting.  Currently, it is thought that two 
dimensional differential gel electrophoresis (2D-DIGE) has the highest sensitivity, 
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reproducibility, and reliability74 in identifying proteomic differences between various samples.  
Because of their widespread use, 2D-DIGE methods are well established75-87.  Briefly, as the 
name implies, 2D-DIGE uses two dimensions to separate the proteins in a sample; the first 
dimension separates proteins based on their individual isoelectric point, and the second 
dimension separates the proteins based on their molecular weight.  The first step in modern 
2D-DIGE methodology is labeling the proteins with a fluorescent tag, then isoelectrically 
focusing the proteins on a pH gradient strip, followed by electrophoresis to separate the 
proteins by their molecular weight using polyacrylamide gels.  The resulting gels are then 
imaged using the fluorescent tags to identify differences between two samples.  The proteins 
appear as spots and significantly, different spots are removed from the gel and identified by 
mass spectroscopy.  As a result, proteins that are differentially expressed between conditions 
are identified through this process, providing a listing of differentially expressed proteins that 
can be used for further study.   
To date, there are no studies using 2D-DIGE to investigate voluntary physical activity.  
While an earlier study by Kromer et al88 investigated locomotor activity as it related to trait 
anxiety88, the tests used in that study were aimed at identifying anxiety and fear and therefore 
did not provide a protein-signature associated with the regulation of voluntary physical activity. 
While there have been no 2D-DIGE studies on voluntary physical activity, there have 
been six studies regarding proteomic differences associated with exercise training74,89-93.  While 
these studies do not provide information on the inherent proteomic differences of low and high 
active subjects, the studies do highlight the effectiveness of the 2D-DIGE model.  Goto et al92 
examined the kidney and Diffee et al91 analyzed cardiomyocytes while four separate studies 
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investigated skeletal muscle74,89,90,93 responses to exercise.  The work by Goto et al92 on the 
kidney identified proteins associated with aging, specifically carbonylated proteins92.   The 
authors hypothesized that the presence of carbonylated proteins led to oxidative stress that 
was in turn an indicator of aging92.  Adding to this literature, Diffee et al91 examined rat 
cardiomyocytes following treadmill running91.  The results showed that following treadmill 
running there was an increase in calcium sensitivity and contractile function of the 
myocardium91.  However, a limitation of this study was that the researchers focused on the 
proteome associated with myosin light chain (MLC) as opposed to the whole myocardial 
proteome.  While not a flaw in the experimental design, this limitation was a result of the 
available technology.  2D-DIGE can be conducted in two ways; the classical method, used by 
Diffee et al91, involved staining the proteins on the gel with silver, then qualitatively visually 
inspecting for differences between samples.  However, new advancements in technology have 
allowed proteins to be fluorescently labeled which results in a more sensitive identification of 
proteomic differences and the ability to quantitatively determine proteomic differences74,89.  
The four studies using 2D-DIGE in skeletal muscle used the fluorescent labeling 
technique and provided evidence for how exercise training can improve skeletal muscle 
contractile function.  Egan et al89 analyzed mitochondrial proteins before and after 14 days of 
endurance training in the vastus lateralis of college-aged males89.  The results showed several 
metabolic adaptations to training, including increases in proteins associated with enhanced flux 
of electrons through the electron transport chain (NADH dehydrogenase, cytochrome c 
oxidase, F type ATP Synthase).  Additionally there was an increase in proteins of the Kreb’s 
cycle (fumarse and pyruvate dehydrogenase).  The authors concluded that through the increase 
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in proteins of the Kreb’s cycle there was an enhanced capacity for substrate utilization through 
improved use of pyruvate leading to increased cofactors (NADH and FADH2)
89.  Thus with an 
increase in cofactors there was a greater ability to generate ATP in the electron transport chain.  
Additionally, Egan et al89 identified proteins that are involved in the antioxidant 
defense and contractile force generation of skeletal muscle.  The antioxidant protein identified 
was Manganese Superoxide Dismutase (Mn-SOD), which removes superoxide radicals following 
the electron transport chain (ETC)89.  The contractile proteins identified were Serca1, myosin 
regulator light chain 2, and tripartite motif 7289.  These proteins appear to influence calcium 
flux in skeletal muscle allowing for a more efficient contraction89.  These results indicated that 
in order to have a higher exercise capacity there was a need to meet the metabolic demand of 
the muscle and increase the efficiency of the contraction, which was obtained through 
increased calcium sensitivity89. 
Interestingly, Gelfi et al74 also identified proteins associated with skeletal muscle 
contractile properties74.  The authors aimed to examine vastus lateralis changes in human 
skeletal muscle of both young and old subjects who participated in exercise74.  Their results 
showed that the young subjects had an over expression of tropomyosin and myosin heavy 
chain as compared to the elderly and further suggested that in order to maintain force 
production and decrease fatigue there was an increase in calcium flux and calcium sensitivity74.  
In a study by Hody et al93, an increase in troponin protein was observed in the rectus femorus 
following high intensity eccentric exercise in college-aged males93.  Yamaguchi et al90 
performed repeated swim tests in rats and compared proteomic changes of the epitrochelearis 
muscle before and after training.  The results showed that following training there was an 
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increase in electron transport chain proteins (ATP Synthase, NADH dehydrogenase, oxoglutare 
dehydrogenase) and an increase in contractile proteins such as myosin light chain and 
parvalbumin90.  Thus, the evidence suggests that in order to have a higher exercise capacity 
there needs to be an increase in calcium handling and substrate utilization.   
These results highlight the utility of using 2D-DIGE to understand the proteomic 
changes following exercise training that allow subjects to have the increased capability to 
perform at higher intensity levels.  However, as with earlier approaches (e.g. QTL, 
transcriptome) the results from these studies do not directly provide mechanistic explanations 
for a particular phenotype.  However, while correlative, the benefit of using 2D-DIGE is that it 
provides targets that are more precise than either QTL analysis or transcriptome expression.  
These proteome-derived targets can then be used in cause-effect based experiments to 
determine functional relevance of these targets.  
1.5 Confirming Candidate Genes’ Involvement in Physical Activity 
While correlation is often the first step in an investigation, cause and effect cannot be 
established using associative research designs.  Thus, it is critical for research designs to test 
the effects of a particular gene on physical activity level.  To provide these causal genetic 
relationships, it is necessary to directly investigate the effect of a specific gene on physical 
activity.  There are a variety of methods that could be used in these types of investigations, 
including the development of transgenic animals, or the use of gene-silencing technology.  
The most common approach used in these types of studies has either been to develop 
transgenic animals with genes deleted (i.e. knocked-out) or increased (i.e. over expressed).  
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Wankhade et al94 used Nhlh2 knockout mouse to investigate the mechanisms associated with 
obesity94.  Nhlh2 knockout mice display higher percent body fat, leptin levels, and body 
temperatures with a decreased physical activity level94.  Additionally, Pistilli et al95 used 
knockout animals to investigate the role of IL-15 receptor alpha on skeletal muscle physiology95.  
IL-15 receptor alpha is a plasma membrane receptor, that when knocked out results in a fiber 
shift from fast twitch to fatigue resistant which results in IL-15 receptor alpha knockout mice 
running longer than their control counterparts do.  Unfortunately, the use of knockout mice in 
these studies also highlight several limitations, including the ability to investigate only a limited 
number of genes at once, developmental issues, and the potential loss of regulatory regions96.   
An example of the limitations with transgenic animals was exhibited by Manzl et al97 with the 
knockout of caspases and Beta cell lymphoma-2 family proteins evident during apoptosis97.  The 
authors stated that the technique, which utilized the cross of the C57Bl/6 mouse strain with the 
129/SvJ mouse strain, led to developmental issues for the animal, such as ocular problems, 
kidney disease and inflammation of the urogenital tract97.  Thus, at least in this case, the 
generation of this knockout animal prevented the desired investigation into programmed cell 
death.  Additionally with a knockout animal it is difficult to knockout multiple genes at once, 
which is a limiting factor in that it has been shown that the regulation of voluntary physical 
activity probably includes multiple genes/proteins as well as epistatic relationships between 
multiple genes12. 
Given the complications of developing and using transgenic animals, there has been a 
search for in vivo techniques that could transiently silence genes in healthy animals.  This 
search has resulted in numerous promising tools identified including antisense 
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oligonucleotides, small interfering RNA (siRNA), phosphorodiamidate morpholino oligomers 
(PMO), and Vivo-morpholinos.  Antisense oligonucleotides and siRNA have been shown to be 
effective at gene silencing yet are highly unstable in body fluids and are rapidly degraded98.  
The decreased stability is due to the fact that oligonucleotides alone are not rapidly up taken 
into the cell, allowing for nucleases to break down the oligonucleotides99.  To alleviate this 
problem, researchers experimented with modifying the oligo’s structure.  The initial type of 
modified oligonucleotides were the PMOs98.  Initial results with PMOs showed an increase 
resistance to degradation by nucleases.  However, in vivo experiments were associated with 
increased toxicity99, thus, decreasing the enthusiasm for their usage.  
Vivo-morpholinos were developed by Morcos and colleagues100 and represent a 
potential in vivo method for transiently silencing specific genes.  Morpholinos are anti-sense 
oligonucleotide (oligo) analogs that bind to complementary RNA sequences and inhibit 
processing of mRNA by blocking translation or splicing of pre-mRNA100,101.  Marcos and 
colleagues100 altered the delivery moiety of morpholinos by using eight guanidinium head 
groups of arginine-rich peptides attached to the anti-sense oligo.  The resulting oligo analog, 
named “Vivo-morpholinos,” is transported into the cell by endocytosis and is protected from 
proteases and nucleases for a length of time (7-14 days) that is dependent upon the gene-
turnover rate100.  In effect, the Vivo-morpholinos provide a method to transiently silence 
specific genes to determine cause-effect relationships.  To date there are only twenty-seven 
studies using Vivo-morpholinos100-126 and all have reported at least 50% knockdown of the 
target with no adverse side effects.  Fourteen of these studies used a mouse 
model100,101,103,110,112,114,119,121-127 with the remaining studies using rats115-117, newts120, chicken 
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embryos106, zebrafish102,104,105  and amphibians107,109,118.  In the mouse model, it has been shown 
that Vivo-morpholinos were equally efficacious with intravenous (IV) or intraperitoneal (IP) 
administration, and recent studies have shown success with direct injection in target tissue115-
117.   
The novelty of Vivo-morpholinos has resulted in limited literature on appropriate 
methods regarding Vivo-morpholinos.  For example, the literature has presented studies with 
appropriate dosage ranges from 6 mg/kg to 17 mg/kg, with once a day treatments to a 
maximum of three consecutive days of treatment122,123.  Initially, it was suggested that in order 
to get longer-term knockdown of targeted proteins, Vivo-morpholino administration had to be 
at the higher dosages122.  However, few studies have employed this route with the majority 
focusing on lower doses and evaluating protein knockdown only 24-48 hours post 
treatment123,124. 
The majority of Vivo-morpholino mammal studies have delivered Vivo-morpholinos via 
IV.  This method of delivery has been shown to be efficacious in knocking down proteins in 
various tissues100.  However, this method of delivery has not been effective at knocking down 
proteins in the brain or cardiovascular system100.  Morcos et al100 has suggested that these 
tissues see a reduced Vivo-morpholino delivery because of a limited ability of Vivo-morpholinos 
to cross membranes in the blood vessels and the heart100.  Additionally it has been shown that 
Vivo-morpholinos cannot pass the blood brain barrier due to the fact that Vivo-morpholinos are 
~10,000 Daltons in size 100 and the blood brain barrier only allows substances less than 400 
Daltons to freely pass128, limiting the application of Vivo-morpholinos to genes in tissues 
outside the brain.  Three studies using rats have used direct tissue injection to deliver Vivo-
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morpholinos to the brain115-117 by using intracranial cannula implantation to direct Vivo-
morpholinos to various brain regions.  The results have shown success with protein knockdown 
in the desired brain region using directly injected Vivo-morpholinos.  However, it is noted that 
protein knockdown only occurred in the targeted brain region and not surrounding 
regions116,117.  If total brain protein knockdown is desired, other strategies involving IV 
administration should be employed, such as using a pharmacological aid to increase blood brain 
barrier permeability128 allowing Vivo-morpholino penetration.  Thus, Vivo-morpholinos are a 
unique tool that will transiently silence genes; however, there are numerous methodological 
questions that need to be resolved so that Vivo-morpholinos can be employed in an optimal 
fashion.  
1.6 Summary 
 Regular physical activity is associated with reductions in rates of several diseases and 
chronic conditions.  Current research has shown that physical activity level is a result of genetic 
influence but the existing data on the genetic regulation of physical activity has focused on QTL 
and gene expression studies.  These studies do not provide mechanistic explanations for the 
genetic regulation of physical activity.  In order to elucidate mechanisms that could influence 
physical activity level, a whole systems proteomic approach to identify protein differences 
between high and low active mice combined with a gene-silencing approach to transiently 
knockdown and confirm identified proteins must be employed.
 
 
*Reprinted with permission from “Vivo-Morpholinos Induced Transient Knockdown of Physical Activity 
Related Proteins” by Ferguson DP, Schmitt EE, Lightfoot JT, 2013. PLos ONE 8(4): e61472. 
doi:10.1371/journal.pone.0061472 
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CHAPTER II 
VIVO-MORPHOLINOS INDUCED TRANSIENT KNOCKDOWN OF PHYSICAL ACTIVITY RELATED  
PROTEINS* 
2.1 Synopsis 
 Physical activity is associated with disease prevention and overall wellbeing.  
Additionally there has been evidence that physical activity level is a result of genetic influence.  
However, there has not been a reliable method to silence candidate genes in vivo to determine 
causal mechanisms of physical activity regulation.  Vivo-morpholinos are a potential method to 
transiently silence specific genes.  Thus, the aim of this study was to validate the use of Vivo-
morpholinos in a mouse model for voluntary physical activity with several sub-objectives.  We 
observed that Vivo-morpholinos achieved between 60 – 97% knockdown of Drd1-, Vmat2-, and 
Glut4-protein in skeletal muscle, the delivery moiety of Vivo-morpholinos (scramble) did not 
influence physical activity and that a cocktail of multiple Vivo-morpholinos can be given in a 
single treatment to achieve protein knockdown of two different targeted proteins in skeletal 
muscle simultaneously.  Knocking down Drd1, Vmat2, or Glut4 protein in skeletal muscle did 
not affect physical activity.  Vivo-morpholinos injected intravenously alone did not significantly 
knockdown Vmat2-protein expression in the brain (p=0.28).  However, the use of a bradykinin 
analog to increase blood-brain-barrier permeability in conjunction with the Vivo-morpholinos 
significantly (p=0.0001) decreased Vmat2-protein in the brain with a corresponding later over 
expression of Vmat2 coincident with a significant (p=0.0016) increase in physical activity.  We 
conclude that Vivo-morpholinos can be a valuable tool in determining causal gene-phenotype 
relationships in whole animal models.  
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2.2 Introduction 
 
 Physical inactivity has been correlated with cardiovascular disease, obesity, type II 
diabetes and some types of cancers5.  With only 3.5% of adults meeting the recommended 
physical activity guidelines6, physical inactivity is the second leading actual cause of death 
(~250,000 cases/year) in the United States7 with an estimated $507 billion a year in health care 
costs5.  Several potential candidate genes associated with the genetic influence on voluntary 
physical activity have been identified5,20,43,46,51,55,117,129,130 with potential regulatory effects both 
in the brain and skeletal muscle.   
 Of the candidate genes identified, Dopamine Receptor 1 (Drd1)5,20,43,55,117, Glucose 
Transporter 4 (Glut4, aka: Slc2a4)51, and Vesicular Monoamine Transporter 2 (Vmat2)45,46,129,131, 
have been the most widely studied in association with voluntary physical activity.  Vmat2 is 
expressed in the brain and skeletal muscle.  Studies examining the nucleus accumbens of the 
brain have shown that Vmat2 stores dopamine in synaptic vesicles45,46,129,131.  A loss of Vmat2 
has been associated with a decrease in physical activity and development of Parkinson’s 
disease45,46.  Another central factor contributing the regulation of physical activity is Drd1; high 
active mice have an under expression of Drd1 which results in a decrease in dopamine turnover 
in the nucleus accumbens43 and a suggested increase in reward driven behavior and voluntary 
physical activity20,43.  It has recently been proposed that Drd1 expression in skeletal muscle 
could have similar effects on physical activity with an increase in D1 receptors (Drd1 and Drd5) 
in skeletal muscle being associated with an increase in muscle force production and prevention 
of atrophy55.  An additional mechanism by which peripheral factors could regulate physical 
activity is through Glut4.  Glut4 transports glucose into skeletal muscle132 and it has been 
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shown that an over expression of Glut4 is associated with a fourfold increase in voluntary 
physical activity51.   
Quantitative genetics rarely identify a mechanistic link relating a potential candidate 
gene to the regulation of a phenotype.  To prove causal relationship, transgenic animals with 
targeted genes knocked-out can be employed.  However, a transgenic approach can be 
confounded by the loss of regulatory regions in the genome as well as developmental issues for 
the animal96.  A tool that could transiently silence a specific gene in vivo without confounding 
effects would be ideal in identifying genes that regulate voluntary physical activity and other 
phenotypes.   
 Morpholinos are anti-sense oligonucleotide analogs that bind to complementary RNA 
sequences and inhibit processing of mRNA by blocking translation or splicing of pre-mRNA100.  
While early versions of morpholinos have been in use for over fifteen years with in vitro 
applications, these early morpholino designs presented several problems that prevented use in 
an in vivo model, including rapid degradation by proteases/nucleases123 and the inability of the 
morpholino to cross membranes110.  These problems were solved when Marcos and 
colleagues100 altered the delivery moiety of morpholinos by using eight guanidinium head 
groups of arginine-rich peptides.  The resulting oligonucleotide analog, termed “Vivo-
morpholinos,” are transported into the cell by endocytosis and protected from proteases and 
nucleases100.  Recently there has been evidence suggesting protein knockdown can be achieved 
equally with intravenous (IV), intraperitoneal (IP), or direct injection into targeted 
tissue100,110,115,123. 
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To date there are only twenty-seven studies using Vivo-morpholinos100-126 and all have 
reported at least 50% knockdown of the target with no adverse side effects.  Fourteen of these 
studies used a mouse model100,101,103,110,112,114,119,121-127 with the remaining studies using rats115-
117, newts120, chicken embryos106, zebrafish102,104,105  and amphibians107,109,118. In the mouse 
models, it has been shown that Vivo-morpholinos were equally efficacious with IV or IP, and 
recent studies have shown success with direct injection in target tissue115,116.  While these 
studies have established the use of Vivo-morpholinos, they were limited in the application 
parameters used.  One of the major limitations of the initial validation studies was the short-
term nature of the studies (e.g. 24-48 hours post treatment) even though it has been 
suggested100 that gene silencing with Vivo-morpholinos will theoretically last much longer (e.g. 
7 days).  Further, the existing Vivo-morpholino studies have only evaluated effects of a single 
Vivo-morpholino without indication of whether multiple genes can be silenced simultaneously.  
Additionally, there has been little success in applying Vivo-morpholinos to the mouse brain100.   
The purpose of this study was to validate the use of Vivo-morpholinos in silencing 
targeted genes in a mouse model of voluntary physical activity.  This study included evaluation 
of the appropriate control, the effectiveness of transporting a Vivo-morpholino across the 
blood brain barrier (BBB) with a pharmacological aid, the ability to combine multiple Vivo-
morpholinos in a “cocktail” to silence multiple genes simultaneously, and whether daily 
physical activity altered the washout time course of an intravenous injected Vivo-morpholino.  
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2.3 Methods 
 Three separate experiments were used to fulfill the purposes of this project.  All 
experiments were approved by the Texas A&M Institutional Animal Care and Use Committee 
(Animal use protocols 2010-256, 2010-187, 2011-140, and 2011-147) and all animals were 
housed in an AAALAC certified vivarium on a 12-hour light/dark cycle with ad libitum access to 
standard chow and water.  Animals were monitored and efforts were taken to ameliorate any 
animal suffering.  All experiments used Vivo-morpholinos ordered in the 400-nmol batch.  
2.3.1 Experiment 1: Evaluation of Vivo-morpholinos’ Gene Silencing in Mouse Activity Model 
 This experiment evaluated the effectiveness of silencing genes in a physical activity 
model using Vivo-morpholinos, a method of Vivo-morpholino delivery across the BBB, as well 
as the appropriate control vehicle.  Eighteen male C57Bl/6J mice (Jackson Labs, Bar Harbor, ME) 
were randomly assigned to one of three treatment groups: 
Group 1) intravenously injected a translation-blocking Vivo-morpholino (11mg/kg)100; 
Gene Tools LLC, Philomath, OR) targeting Vmat2 (Vmat2 group, n=6);   
Group 2) Intravenously injected a Vivo-morpholino scramble control (11mg/kg) which 
consisted of vehicle plus an oligonucleotide target (5’-CCTCTTACCTCAGTTACAATTTATA-
3’) that did not correspond to murine mRNA (Scramble group, n=6); and   
Group 3) An intravenously injected control group that received an equal volume (110ul) 
of physiological saline (Saline group, n=6).   
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Preliminary experiments determined that systemically delivered Vivo-morpholinos did 
not knockdown brain proteins133.  Thus, to facilitate Vivo-morpholino transport across the BBB, 
all treatment groups received the bradykinin analog RMP-7 (6.5µg/kg; Bachem, Prussia, PA)128.  
Pharmacological studies have shown that using endogenous analogs of bradykinin134 increase 
permeability of the BBB while maintaining physiological function of the animal128.  Bradykinin 
activates β2 receptors on endothelial cells of cerebral capillaries thereby disengaging tight 
junctions and causing an increase in permeability of cerebral blood vessels128,134.  RMP-7 is a 
bradykinin analog that has several benefits over bradykinin; specifically RMP-7 resists 
degradation, has little to no toxicity to the brain, can be administered intravenously, and is fast 
acting producing a result within 60 seconds of administration134.  RMP-7 was initially developed 
as a delivery method for chemotherapeutics in brain glioma patients with studies showing a 
linear dose response between RMP-7 and BBB permeability in conjunction with a variety of 
chemotherapeutics128.   
At eight weeks of age mice were individually housed with running wheels equipped 
with computers (Sigma Sport, St. Charles, IL) to measure average daily distance run12, and 
beginning at nine weeks of age, completed a week of baseline wheel running.  At ten weeks of 
age, mice were randomly assigned to one of the three treatment groups and received a tail vein 
injection of the specific treatment for three consecutive days.  At 11 weeks of age (4 days post 
the last injection) half the cohort was sacrificed (n=3 per treatment group).  The activity of the 
remaining mice was monitored for an additional week (recovery) and the mice were then 
sacrificed. 
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 At sacrifice, mice were anesthetized using vaporized isoflurane followed by cervical 
dislocation.  The soleus (peripheral slow twitch muscle) and nucleus accumbens (reward center 
of the brain) were removed and flash-frozen for later analysis.  Gene silencing was evaluated by 
determining protein knockdown using standard SDS-Page and Western blotting techniques.  
Briefly, proteins were extracted by placing the tissue in lysis buffer and homogenizing the tissue 
with a motor and pestle.  Protein concentration was determined by Bradford assay to ensure 
equal amount of protein loading per sample on the gel.  The proteins were separated by SDS-
Page, and then transferred to a nitrocellulose membrane with transfer confirmed by Ponceau S 
stain.  Membranes were incubated overnight in 1:1000 ratio of primary antibody recognizing 
Vmat2 (Cell Applications, San Diego, CA) and blocking buffer (5% Nonfat Dried Milk, 0.5% 
Tween 20).  Membranes were then incubated in the secondary horseradish peroxidase 
antibody (Cell Signaling Technology, Beverly, MA).  Chemiluninescence was imaged with a 
Flurochem analyzer (Derbyshire, UK) and the blot was analyzed using the individual protein 
band’s optical density that allowed for a semi-quantitative estimate of protein knockdown. 
 The Western blot optical densities were analyzed using one-way ANOVA to compare 
Vmat2 protein expression between the treatments with an a priori alpha level of 0.05.  Activity 
data was analyzed using a 3x3 ANOVA with the main effects being treatment group (i.e. Vmat2, 
Saline, or Scramble) and week of treatment (i.e. baseline, injection, or recovery).  If there was a 
significant main-effect, a Tukey’s HSD post hoc (p<0.05) test was employed.  All statistical tests 
were carried out using GraphPad Prism 5 (GraphPad Software Inc, La Jolla, CA).  
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2.3.2 Experiment 2: Determination of Vivo-morpholino Washout Period 
 To evaluate if physical activity altered the efficacy of the Vivo-morpholino, 24 eight 
week old C57Bl/6J male mice (Jackson Labs, Bar Harbor, ME) were individually housed and 
randomly assigned to either a running wheel group (n=12; unlocked wheels) or a fixed wheel 
group (n=12; locked wheels).  The running wheel group had free moving wheels attached to a 
computer as described in Experiment 1.  Each mouse in the fixed running wheel group had a 
running wheel that was secured to prevent wheel movement.  Beginning at nine weeks of age, 
daily distance was measured in the running wheel group using methods from Experiment 1.  At 
ten weeks of age one mouse from each group was sacrificed to establish a baseline level of 
Vmat2 protein expression, while the remaining mice received a concurrent tail vein injection of 
RMP-7 (6.5ug/Kg)128 and a Vivo-morpholino targeting Vmat2 (11mg/Kg)100 for three consecutive 
days.  Each day thereafter, one mouse was sacrificed from each group to determine the 
washout of the Vivo-morpholino and whether exposure to activity affected protein knockdown.  
 On the day of sacrifice, mice were euthanized using vaporized isoflurane and cervical 
dislocation, with subsequent harvesting of the soleus and nucleus accumbens.  Afterwards, 
proteins were extracted from each sample and Vmat2 expression, as well as α-synuclein (Cell 
Signaling, Danvers, MA), which has been shown to be an indicator of Vmat2 transcription135, 
were determined using Western Blot techniques described in Experiment 1.  The washout data 
was then analyzed for linearity and if nonlinear, nonlinear regression approaches were used to 
obtain R2 values for the washout curves.  The nonlinear data was then log transformed to meet 
the parameters of a linear regression, which allowed the comparison of the regression 
parameters between the locked and unlocked running wheel groups.  A p value of 0.05 was set 
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a priori to determine if the slopes and y intercepts were different from each other.  If there 
were no differences between the locked and unlocked wheel groups, the data points were 
pooled.  To facilitate the comparison of baseline physical activity across the treatment protocol, 
average daily distance measurements were pooled in animals sacrificed in days 1-5 and days 6-
11 of the protocol and compared using a one-way ANOVA (a priori alpha value = 0.05). 
2.3.3 Experiment 3: Utilization of a Vivo-morpholino Cocktail 
  Twelve, eight-week old male C57Bl/6J mice (Jackson Labs, Bar Harbor, ME) were 
individually housed with running wheels as described in Experiment 1 to measure average daily 
distance run.  At nine weeks of age mice completed a week of baseline wheel running and then 
at ten weeks of age, randomly received a tail vein injection of either the Vivo-morpholino 
cocktail (n=6) containing a Vivo-morpholino targeting Drd1 (11mg/kg)100 and another Vivo-
morpholino targeting Glut4 (11mg/kg)100 or physiological saline (n=6) for three consecutive 
days.  Physiological saline was used as a control since Experiment 1 showed no difference in the 
activity response of physiological saline and Vivo-morpholino scrambled control (see Results).  
At 11 weeks of age (four days post-last injection), half the cohort was sacrificed to evaluate the 
initial protein knockdown efficacy of the Vivo-morpholino cocktail.  The remaining mice ran for 
one week and were then sacrificed.  Upon sacrifice, the soleus was harvested and protein 
expression of Drd1 (Cell Applications, San Diego, CA) and Glut4 (Cell Applications, San Diego, 
CA) as well as the potential compensatory proteins dopamine receptor 5 (Drd5, Proteintech 
Group Inc, Chicago, IL) and glucose transporter 1 (Glut1, Cell Applications, San Diego, CA) were 
determined using standard Western blotting techniques, as described in Experiment 1.  Similar 
statistical analysis was used as in Experiment 1 with the exception of a 2x3 ANOVA with the 
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main effects being treatment (Saline or Vivo-morpholino cocktail) and treatment week 
(Baseline, Injection, or Recovery).  
2.4 Results 
2.4.1 Experiment 1: Evaluation of Vivo-morpholinos in Activity Model 
 In the brain, treatment with a Vivo-morpholino targeting Vmat2 did not result in a 
significant knockdown of Vmat2 expression in the nucleus accumbens of the brain four days 
after the last Vivo-morpholino injection as compared to saline or scramble treatment (Figure 
2.1, Panel A).  However, there was a 79% knockdown (p=0.04) of Vmat2 in the soleus four days 
post-injection as compared to both saline and scramble (Figure 2.2, Panel A).  Surprisingly, 
during the recovery week (11 days post treatment) Vmat2 protein level had a significant 354% 
over expression in the soleus of the Vmat2-Vivo-morpholino group compared to the saline and 
scramble treatment (Figure 2.2, Panel B, p=0.03).  In the nucleus accumbens (Figure 2.1) and 
the soleus (Figure 2.2) there was no difference in Vmat2 expression between saline and 
scramble treatments.     
The initial reduction of Vmat2 in the soleus did not affect daily physical activity (Figure 
2.3).  However, the Vmat2 group had a significant 139% increase in activity during the recovery 
week as compared to the baseline and injection week (Figure 2.3, p=0.001), which 
corresponded to the Vmat2 over expression observed in the soleus eleven days post-injection 
(Figure 2.2, Panel B). 
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2.4.2 Experiment 2: Determination of Vivo-morpholino Washout Period 
  The evaluation of the washout time course of Vivo-morpholinos targeting Vmat2 
showed there was a significant (p=0.001) 55% knockdown of Vmat2 in the soleus on Days 2-6 
(Figure 2.4 Panels A and C) with a significant 129% over expression observed on Day 9 
(p=0.001).  There was no difference (p=0.74) between the washout curves for the animals who 
had access to a running wheel (R2=0.65) compared to those that had a locked running wheel 
(R2=0.55) (Figure 2.4 Panel B). 
In the nucleus accumbens, there were similar observations as in the soleus.  There was 
a significant 74% knockdown in Vmat2 (Figure 2.4 Panels D and F) on Days 5-6 (p=0.001) with a 
988% over expression on Day 11 (p=0.001).  Additionally there was no difference in the 
washout curves (p=0.66) for animals on wheels (R2=0.99) or locked wheels (R2=0.99) (Figure 2.4 
Panel E). 
To confirm the over expression of Vmat2, western blot analysis was performed probing 
for α-synuclein, which is an indicator of Vmat2 transcription135.  The results showed that in the 
brain on Days 2 and 7 there was a 275% increase α-synuclein protein level (Figure 2.5). 
There was no difference (p>0.05) in physical activity level of the running wheel group 
between the baseline week and days 1-5 post-injection (Figure 2.6).  During days 6-11 of the 
washout protocol there was a significant 164% increase in physical activity (p=0.0016) versus 
baseline and days 1-5, corresponding to the increase in Vmat2 expression during the same time 
period (Figure 2.4).  
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2.4.3 Experiment 3: Utilization of a Vivo-morpholino Cocktail 
 Western blot analysis showed that there was significant knockdown in Drd1 (97%) 
protein (Figure 2.7, Panel A, p=0.01) and Glut4 (60%) protein (Figure 2.7, Panel A, p=0.042) in 
the soleus four days after the last injection.  Expression of both Drd1 and Glut4 returned to 
control levels during the recovery week (11 days post injection, Figure 2.7, Panel B).  With the 
Vivo-morpholino cocktail treatment (Drd1 and Glut4) there was no change in physical activity at 
any time period (Figure 2.8, p=0.15).   
 To evaluate potential compensation for the decreases in Drd1 and Glut4, Drd5 and 
Glut1 were probed by western blotting (Figure 2.9).  There was no difference in Drd5 protein 
levels between control and treatment at four days post treatment (p=0.22) or eleven days post 
treatment (p=0.93).  There was also no difference in Glut1 protein levels between control and 
treatment at four days post treatment (p=0.56) or eleven days post treatment (p=0.36).   
2.5 Discussion 
A molecular biology tool that can transiently silence genes in a whole-animal model will 
significantly advance the capability to determine cause-effect relationships between specific 
genes and targeted phenotypes.  We have found that the use of Vivo-morpholinos targeting 
Vmat2, Drd1, and Glut4 resulted in transient protein knock-down in the skeletal muscle up to 
four days after the last application.  While the use of a pharmacological agent to facilitate Vivo-
morpholino delivery across the blood brain barrier seemed promising, our results indicate 
marginal knockdown in the brain as compared to the soleus when using RMP-7.  Further, we 
observed that concurrent physical activity did not influence the action of Vivo-morpholinos on 
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Vmat2 protein expression.  Maybe most importantly, we also observed that the use of multiple 
Vivo-morpholinos in a cocktail would knock down more than one protein at a time in skeletal 
muscle.  Interestingly, while initial knockdown of these proteins did not affect physical activity, 
we observed an increased physical activity coincident with post-washout over expression of 
Vmat2. 
The search for an in vivo technique to transiently silence genes has been pursued for 
several decades with numerous promising tools identified including antisense oligonucleotides, 
small interfering RNA (siRNA), and phosphorodiamidate morpholino oligomers (PMO).  
Antisense oligonucleotides are effective at gene silencing yet are highly unstable in body fluids 
and are rapidly degraded123.  Initially, siRNA promised to transiently silence genes but 
presented difficulty with in vivo applications125, which has limited siRNA’s usefulness in 
integrative physiology.  PMOs resist degradation in vivo yet have been associated with 
increased toxicity123.  Morpholinos, which are a form of antisense oligonucleotides, have had 
several modifications to their structure to limit toxicity and improve gene silencing which led to 
the development of the more stable Vivo-morpholino100.  Additionally, the fact that we 
observed no change in daily physical activity with the vivo-morpholino delivery vehicle 
(scramble) makes the Vivo-morpholino ideal for the investigation of candidate genes associated 
with physical activity.      
Our results showed that Drd1-, Glut4-, and Vmat2-targeted Vivo-morpholinos 
significantly knocked down Drd1, Glut4, and Vmat2 protein expression in skeletal muscle by an 
average 97%, 60%, and 79%, respectively.  Furthermore, the use of the Vivo-morpholino 
cocktail showed that simultaneous protein knockdown was possible.  Previous studies have 
 
 
42 
 
shown that treatment with Vivo-morpholinos at a similar dosage as used in this study (i.e. 
11mg/kg) resulted in 50-70% knockdown105,136 similar to the knockdown amounts we observed.  
Recent literature122 suggests that to obtain 100% protein knockdown, the Vivo-morpholino 
dosage must be 160% greater than the amount prescribed by the manufacturer (i.e. 17.6 
mg/kg) or the Vivo-morpholino injections must be given regularly over the course of the 
study123,124.  The fact that there were differences in the magnitude of Drd1 and Glut4 
knockdown suggests that the nature of the target gene also may play a role in the magnitude of 
gene silencing.  Genes coding for proteins that exhibit faster turnover rates in skeletal muscle 
may require the higher Vivo-morpholino dose.  Therefore, protein turnover characteristics 
should be considered as a design parameter in Vivo-morpholino protocols. 
Our initial results with Vivo-morpholinos in brain tissue were not promising due to a 
potential lack of BBB penetration133.  Vivo-morpholinos are ~10,000 Daltons in size and the BBB 
prevents substances greater than 400 Daltons from reaching the brain128, thus we utilized RMP-
7 as means to facilitate Vivo-morpholino delivery across the BBB.  Unfortunately, in spite of the 
potential benefits of using RMP-7, Experiment 1 did not show significant knockdown in the 
nucleus accumbens of Vmat2 protein when using RMP-7 on day four after the injection.  
Interestingly, we did observe Vmat2 knockdown in the nucleus accumbens in Experiment 2 on 
Days 5 and 6 after the last injection, which was outside of our measurement range in 
Experiment 1.  We suspect that due to the high activity of the dopamine system in the brain137-
139, there may be a decreased protein turnover rate of Vmat2 in the brain as compared to 
skeletal muscle137,140-142 resulting in a slower protein turnover rate leading to a slower 
knockdown time course of Vmat2 in the brain.  Thus, while the use of RMP-7 appears to have 
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facilitated some knockdown of Vmat2 in the brain, knockdown of brain genes using Vivo-
morpholinos needs to be carefully designed to optimize both knock-down magnitude and time-
course.  
Surprisingly, in both Experiments 1 and 2, we observed a rebound over expression of 
Vmat2 protein compared to baseline during the recovery week in both skeletal muscle and 
nucleus accumbens.  To our knowledge, this rebound phenomena has not been reported in the 
Vivo-morpholino literature.  We would suggest that this rebound over expression was actually 
the result of the feedback loop that controls Vmat2142.  Speculatively, with the blocking of 
Vmat2 mRNA and a reduction of Vmat2 protein concentration, the cell would have been 
stimulated to transcribe more Vmat2.  With subsequent Vmat2 production being blocked by 
the Vivo-morpholino, the stimulus to produce more Vmat2 mRNA would become further 
elevated compared to the initial days of treatment.  Once the Vivo-morpholino was degraded 
and removed, the elevated signal to produce Vmat2 would result in an increased translation of 
Vmat2 mRNA142 and over expression of Vmat2 protein.  This hypothesis is supported by our 
observation of a significant increase in α-synuclein in the nucleus accumbens on Day 2, with a 
continued increased signaling from Day 7 and peaking on Day 10 (Figure 2.5).  Whereas α-
synuclein has been observed to be an indicator of the cell’s stimulus to transcribe Vmat2135, it 
appears that once Vmat2 was knocked down there was an increase in the stimulus to 
transcribe Vmat2 which resulted in the over expression of Vmat2 in the recovery week.  While 
we did not observe a rebound over expression with either of the other genes we investigated 
(Drd1 and Glut4), the possibility of such a rebound effect occurring with other genes is 
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potentially an intriguing way to use Vivo-morpholinos to explore consequences of both gene 
under expression and over expression in the same model. 
It has been previously suggested that Drd1, Glut4, and Vmat2 are potential candidate 
genes for the regulation of physical activity20,43,45,46,55 with Glut4 in particular, showing a direct 
effect on activity when over expressed51.  Thus, we were somewhat surprised that knockdown 
of both Drd1 and Glut4 simultaneously in soleus (Experiment 3) did not affect activity levels.  
However, our observed lack of effect of Glut4 and Drd1 knockdown on physical activity in spite 
of an observed 60% and 97% protein reduction, respectively, could have reflected a general 
redundancy in these physiological systems.  For example, it has been shown that with a 50% 
reduction in Glut4 there is no apparent change in muscle physiology because of a 
compensatory Glut1 over-expression for the loss of Glut4143,144.  Therefore,   we evaluated 
possible compensation in these two systems by analyzing Drd5 and Glut1 protein levels.  We 
observed no differences in Drd5 or Glut1 levels between control and treatment groups 
suggesting that compensation for the knock down of Glut4 or Drd1 did not occur and therefore, 
neither Glut4 nor Drd1 are primary peripheral regulating genes in voluntary activity.  However, 
in spite of these results, it is clear that future studies can take advantage of the use of vivo-
morpholino cocktails to silence multiple genes at once to consider their phenotypic effects. 
Vmat2 was an attractive knockdown target for the regulation of physical activity given 
its proven role in the development of Parkinson disease46.  However, we observed no change in 
activity with a decrease in peripheral Vmat2 in Experiments 1 and 2.  However, the rebound of 
Vmat2 observed in the soleus (Experiment 1 and 2) and nucleus accumbens (Experiment 2) 
along with the associated increase in physical activity could provide a potential explanation for 
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the regulation of voluntary physical activity.  It has been shown that the dopamine system in 
skeletal muscle affects muscle force production55 and in the brain affects reward driven 
behavior43.  When mice are given, artificial dopamine there is an associated hyperactivity 
response137,138,140,145.  We would suggest that as the effects of the Vivo-morpholinos wore off 
and Vmat2 expression returned and surpassed baseline, there was an increase in extracellular 
dopamine that elicited the hyperactive effects similar to artificially administering dopamine.  
Further, this extracellular dopamine would have increased skeletal muscle tone and force 
production55,146 as well as reward driven behavior43, which would have further increased 
physical activity.  
 The purpose of these experiments was to evaluate the efficacy of a potential transient 
gene-silencing tool, the Vivo-morpholino, when used in a physical activity model for an 
extended period of time.  We observed that Vivo-morpholinos that targeted Vmat2, Drd1 or 
Glut4 significantly reduced associated protein expression in skeletal muscle up to four days 
after treatment with a subsequent recovery to baseline levels in Drd1 and Glut4  and with an 
over expression in Vmat2.  Physical activity during the treatment did not affect the time course 
of protein knockdown.  The delivery vehicle used (scramble Vivo-morpholino) did not affect 
protein knockdown or physical activity.  Further, we found that multiple Vivo-morpholinos 
given in a cocktail knocked down multiple proteins simultaneously.  While knocking-down any 
of the targeted genes did not result in hypothesized reductions in physical activity, a rebound of 
Vmat2 protein was associated with an increase in physical activity during the same time as the 
rebound.  We conclude that the use of Vivo-morpholinos can be a powerful tool to transiently 
silence specific genes and determine whether those genes are causally related to a phenotype 
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of interest, especially when the targeted gene’s protein characteristics, such as turnover rate 
and location, are used to strengthen the research design.   
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CHAPTER III 
THE DIFFERENTIAL SKELETAL MUSCLE PROTEOME IN HIGH AND LOW ACTIVE MICE 
3.1 Synopsis 
 Physical inactivity contributes to cardiovascular disease, type II diabetes, obesity and 
some types of cancer with an estimated $507 billion per year in related health care costs.  
While the literature is clear that there is genetic regulation of physical activity with existing 
gene knockout data suggesting that skeletal muscle mechanisms contribute to the regulation of 
activity, actual differences in end-protein expression between high- and low-active mice have 
not been investigated.  This study used two-dimensional differential gel electrophoresis 
coupled with mass spectrometry to evaluate the proteomic differences between high active 
(C57L/J) and low-active mice (C3H/HeJ) in the soleus and extensor digitorum longus (EDL).  
Furthermore, Vivo-morpholinos were used to transiently knockdown candidate proteins to 
confirm their involvement in physical activity regulation.  The high-active mice over expressed 
21 proteins in the soleus and 3 in the EDL compared to the low-active mice.  The low-active 
mice over expressed 21 proteins in the soleus and 5 in the EDL compared to the high-active 
mice.  Primarily, proteins with higher expression patterns generally fell into the calcium-
regulating and Kreb’s (TCA) cycle pathways in the high-active mice (e.g. Annexin A6 p=0.0031; 
Calsequestrin 1 p=0.000025), while the over expressed proteins in the low-active mice 
generally fell into electron transport chain related pathways (e.g. ATPase, p=0.031; NADH 
dehydrogenase, p=0.027).  Transient knockdown of Annexin A6 and Calsequestrin 1 protein in 
skeletal muscle of high active mice with Vivo-morpholinos resulted in decreased physical 
activity levels (p=0.001).  These data suggest that high- and low-active mice have unique 
 
 
48 
 
protein expression patterns and that each pattern contributes to the peripheral capability to be 
either high- or low-active, suggesting that different specific mechanisms regulate activity 
leading to the high- or low-activity status of the animal. 
3.2 Introduction 
 Regular physical activity prevents cardiovascular disease, obesity, and type II diabetes5.   
However, when objectively measured, only 3.5% of adults meet the recommended daily 
physical activity guidelines7.  Recent data has shown that physical activity levels are a result of 
genetic influence5,11,14,29,30,35,147; however, the identity of the genetic mechanisms involved 
remain unclear in spite of efforts to determine genomic variance and transcripts associated 
with activity levels.  Genetic variance and transcript data only illustrate a portion of the 
potential regulatory mechanisms for voluntary physical activity and neither avenue of 
investigation accurately predict the final protein products that are associated with the 
phenotype36,148,149.  
 Two dimensional differential gel electrophoresis (2D-DIGE) is an accurate and reliable 
method to identify proteomic differences in skeletal muscle74,89,90; however, 2D-DIGE has not 
been used in the physical activity literature, but rather in literature focusing on proteomic 
changes following sprint or endurance exercise training74,89,90,93.  While, adaptation to exercise 
is an important field of study for physiology, these studies do not provide information on the 
inherent protein expression differences between high and low active individuals.   
 While 2D-DIGE paired with mass spectroscopy provides protein identification, the 
results are correlative with end phenotype.  In order to determine causal mechanisms 2D-DIGE 
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results must be confirmed with an in vivo method to knockdown identified proteins in order to 
determine the proteins’ role in the phenotype of interest.  Vivo-morpholinos are a novel tool 
developed by Morcos and colleagues100 that allows for transient knockdown of a targeted 
protein.  Our lab has evaluated Vivo-morpholino effectiveness in the physical activity model in 
terms of delivery to brain and skeletal muscle tissue, washout time courses of Vivo-
morpholinos, as well as appropriate Vivo-morpholino dosages and controls150.  Our results 
show that Vivo-morpholinos are an ideal tool to be paired with 2D-DIGE and mass spectroscopy 
in order to identify mechanisms associated with the physical activity phenotype150.   
Kelly et al15 has hypothesized that the biological regulation of activity that arises 
through genetic control mechanisms has both central (brain) and peripheral (skeletal muscle) 
components.  Indeed, several studies have shown that alteration of skeletal muscle gene 
expression (e.g. Glut451; IL-15Rα151) without alteration in central brain gene expression can 
markedly change voluntary physical activity.  Thus, the purpose of this study was to identify 
proteomic differences between high- and low-active mice in slow and fast twitch skeletal 
muscle, followed by causal determination of the role of strong candidate proteins in regulating 
physical activity.  
3.3 Methods 
This study was conducted in two phases:  the first was a proteome determination 
phase where differential proteins were identified from the inherent skeletal muscle proteome 
of high- and low-active mice.  The second phase was to determine whether highly significant 
proteins determined in phase one were causally linked to physical activity using transient gene-
silencing techniques.  The Institutional Animal Care and Use Committee at Texas A&M 
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University approved all procedures in this study. 
3.3.1 Experiment 1: Proteome Determination  
Twelve, eight week old C3H/HeJ mice (6 male and 6 female) and 12, eight-week-old 
C57L/J mice (6 male and 6 female) were obtained from The Jackson Laboratory (Bar Harbor, 
ME).  Previous extensive work from our lab has shown that the C3H/HeJ mice have a lower 
physical activity level (1.2 ± 1.7 km run per day) as compared to the C57L/J (10.7 ± 2.7 km run 
per day) mice11-13,30,35,43,44,152.  Our standard operating procedure has been to monitor physical 
activity in each mouse for at least seven days.  Where at eight weeks of age mice are 
individually housed with running wheels equipped with computers (Sigma Sport, St. Charles, IL) 
to measure average daily distance run12.  However, due to our concern that wheel running 
would alter protein expression in the skeletal muscle153, the mice, after one week of 
acclimation, were individually housed with locked running wheels for one week.  Locked 
running wheels were used to simulate the environment of previous physical activity studies 
from this lab12 while preventing wheel running.  All animals were housed in an AAALAC certified 
vivarium maintained at 18–21°C and 20–40% humidity with 12:12-h light dark cycles that 
initiated at 6:00 AM.  Food (Harland Teklad 8604 Rodent Diet, Madison, WI) and water were 
provided ad libitum.  Body masses (to the nearest 0.1 g) were collected once per week 
throughout the study and body composition was determined prior to sacrifice using a GE Lunar 
Piximus dual X-ray absorptiometer (GE Healthcare Waukesha, WI).   
 
At 10 weeks of age, mice were anesthetized using vaporized isoflurane followed by 
cervical dislocation.  The soleus (peripheral slow twitch skeletal muscle) and extensor digitorum 
longus (EDL, peripheral fast twitch skeletal muscle)154 were removed and flash frozen for later 
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analysis.  Subsequently, for protein extraction, tissues were placed in Tris/CHAPs Lysis buffer 
and homogenized.  Protein concentration was determined by Bradford assay.  Due to 
differential protein concentrations in the soleus and EDL and in order to obtain optimal results, 
the soleus samples were isoelectric focused on 13 cm immobilized pH gradient (IPG) strips 
while the EDL samples were run on a 24 cm IPG strips.  
 Two-dimensional differential in-gel electrophoresis (2-D DIGE) and protein 
identification was initiated using techniques previously published155,156.  In brief, protein was 
precipitated with chloroform/methanol and dissolved in DIGE labeling buffer (7 M urea, 2 M 
thiourea, 4% CHAPS, 30 mM Tris, pH 8.5).  Samples were fluorescently labeled by combining 
either 50 µg of EDL protein or 45 µg of soleus protein with 200 pmol CyDye DIGE Fluors (GE 
Healthcare).  One sample was labeled with Cy3 while the other was labeled with Cy5 to allow 
for preferential labeling.  A pooled sample containing equal amounts of each sample was 
labeled with Cy2.  The labeling reactions were quenched with 10 mM lysine.  The samples were 
randomly mixed so that one Cy3 and one Cy5-labeled sample were loaded on a single gel, along 
with the Cy2-labeled pooled sample, which was used as an internal standard and allowed for 
each resolved protein to be semi-quantitatively assessed relative to the standard within and 
between all gels, thereby minimizing gel-to-gel variation.  Unlabeled protein samples were 
added to the labeled proteins (800 µg total protein for EDL and 328.5 µg total protein for 
soleus) and used to rehydrate the IPG strips (either 24 cm, pH 4-7, ImmobilineTM DryStrip for 
EDL or 13 cm, pH 4-7, ImmobilineTM DryStrip for soleus, GE Healthcare) by passive diffusion.  
Isoelectric focusing was performed on an IPGPhor (GE Healthcare) with a program of 500 volts 
for one hour followed by 1000 volts for one hour followed by a linear gradient to 8000 volts 
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until approximately 60,000 Vhr for EDL or 40,000 Vhr for soleus was achieved.  The focused 
strips were equilibrated in two steps: 15 minutes in SDS equilibration buffer I (6M urea, 2% SDS, 
30% glycerol, 50 mM Tris, pH 8.8, 0.01% bromophenol blue, and 10 mg/ml DTT) followed by 15 
minutes with equilibration buffer II in which the DTT was replaced by 25 mg/ml iodoacetamide.  
The equilibrated IPG strips were placed directly on top of polymerized 12% SDS gels and 
covered with low-melt agarose.  Gels were run in cooled tanks at 1 watt per gel until the dye 
front was at the bottom of the gel. 
Gel images were obtained using a TyphoonTM Trio, Variable Mode Imager (GE 
Healthcare).  DeCyder software (GE Healthcare, version 6.5) was used to detect spots, subtract 
background, and to normalize spots against the pooled standard.  Further, DeCyder was used to 
match spots between gels and determine significant changes in protein expression (p<0.05) and 
the average ratio.  Average ratio was derived from the normalized spot volume standardized 
against the intra-gel standard thus providing a measure of the magnitude of expression 
differences between identified proteins.  Spot detection and matching were verified visually.  
Gels to be used for spot picking were fixed in 10% methanol and 7.5% acetic acid overnight, and 
post-stained with Deep PurpleTM Total Protein Stain (GE Healthcare) and imaged on the 
Typhoon.  The post-stained spots were matched to the CyDye gel images using DeCyder 
software.  Picking and digestion were performed using Ettan robotic components (GE 
Healthcare). 
Spots that showed significant (p<0.05) differences in abundance between low active 
(C3H/HeJ) and high active (C57L/J) mice were robotically picked, washed, and digested (GE 
Healthcare, Ettan system) with recombinant porcine trypsin (Promega, Madison, WI) as 
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described elsewhere83.  Extracted tryptic peptides were concentrated by SpeedVac and 
analyzed by nano-electrospray ionization/ion trap mass spectrometry (LC/MS/MS with an LTQ 
XL linear; ThermoFinnigan, San Jose, CA).  Subsequently, peptides from the MS were identified 
using the MASCOT search engine.  The MASCOT program (v2.2) searched the mouse genome 
using the following parameters for protein identification: 1) one missed cleavage by trypsin; 2) 
monoisotopic peptide masses; 3) peptide mass tolerance of 1.2 Da; and 4) fragment mass 
tolerance of 0.8 Da.  Further, oxidation of methionine and carbamidomethylation of cysteine 
were taken into consideration by MASCOT in the protein identification.  By meeting these 
parameters, the peptides were matched to proteins at a significance level of p < 0.05.  Protein 
identifications were verified by Scaffold (Proteome Software, Portland, OR).  Proteins were 
then categorized based on their function using String 9.0157. 
From the 2D-DIGE results, two highly significantly expressed (p<0.001) proteins 
(Annexin A6 – Anxa6, and Calsequestrin 1 – Casq1, see results) were validated using standard 
western blot techniques.  Briefly, proteins from three randomly chosen samples of each strain 
were separated by SDS-Page, and then transferred to a nitrocellulose membrane with transfer 
confirmed by Ponceau S stain.  Membranes were incubated overnight in 1:1000 ratio of primary 
antibody recognizing Anxa6 (Biorbyt, San Francisco CA) or Casq1 (GeneTex, Irvine, CA) and 
blocking buffer (5% Nonfat Dried Milk, 0.5% Tween 20).  Membranes were then incubated in 
the secondary horseradish peroxidase antibody (Cell Signaling Technology, Beverly, MA).  
Chemiluninescence was imaged and all analysis was performed with a Flurochem analyzer 
(Derbyshire, UK).  Additionally GAPDH (GeneTex) was analyzed as a loading control.  Western 
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blots were analyzed using the individual protein band’s optical density that allowed for a semi-
quantitative estimate of protein level.   
In an effort to elucidate potential protein networks associated with the highly 
significantly expressed candidate proteins, we conducted co-immunoprecipitation (CoIP) 
experiments using the Pierce Crosslink IP Kit (Thermo Scientific, Rockford, IL).  Briefly, the CoIP 
antibody (Anxa6 or Casq1) was bound to Protein A/G Agarose resin.  A non-specific control was 
used (no antibody) in order to establish a “background” effect.  The antibody resin was then 
incubated with the whole sample extract that contained the protein antigen of interest, 
allowing the antibody:antigen complex to form.  After washing to remove non-bound 
components of the sample, the antigen was recovered by dissociation from the antibody with 
elution buffer158.  The eluted sample was then run on an SDS page.  As the sample entered the 
10% running gel, the electrophoresis was stopped, proteins were stained with Coomassie blue, 
and the bands were cut from the gel, digested, and subjected to mass spectroscopy for 
identification as described previously. 
3.3.2 Experiment 2: Role of Candidate Proteins in Physical Activity 
 The 2D-DIGE results showed that Anxa6 and Casq1 were highly significantly over 
expressed (p<0.001) in high active mice.  Given that both proteins are involved in calcium 
homeostasis of skeletal muscle60,69, Anxa6 and Casq1 were determined to be strong candidates 
for the peripheral regulation of physical activity and selected for further evaluation using 
transient gene silencing Vivo-morpholinos.  Forty-two high-active C57L/J male mice were 
obtained from The Jackson Laboratory.  Male mice were chosen since there was no difference 
in protein expression between males and females (see 2D-DIGE results) and to prevent any 
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effects of the estrous cycle of female mice on physical activity response159 .  The mice were 
randomly divided into three treatment groups: 1) Control mice (n=15) that were treated with 
physiological saline; 2) Anxa6-targeted mice (n=15); and 3) Casq1-targeted mice (n=12).  
Previous results from our lab have shown that physiological saline is an appropriate control as 
compared to Vivo-morpholino scramble in terms of physical activity response, and expression 
of targeted protein150. 
At eight weeks of age, mice were individually housed on running wheels with ad libitum 
access to food and water for three days to establish baseline wheel running.  Following baseline 
wheel running the running wheel was locked for four days in order to mirror the settings of the 
2D-DIGE study (described previously) and prevent the expression of proteins because of a 
training effect.  At the end of the first week (three days running, four days locked wheel), three 
mice were euthanized as described above and the soleus and EDL were extracted to determine 
baseline levels of Anxa6 and Casq1 expression using western blotting techniques described 
earlier.  During the subsequent treatment week, mice were administered either Vivo-
morpholinos targeting Anxa6 or Casq1 (11mg/kg, GeneTools, LLC, Philomath, OR) or equal 
volume physiological saline (~56 ul) via tail vein injection on treatment weekdays 1, 3, 5, and 7.  
After the Vivo-morpholino-treatment week, mice were allowed to recover for one week (Days 
8-15).  Throughout both the treatment and recovery weeks, the wheels were unlocked and 
activity was measured using the previously described methods.   
To establish the protein expression pattern during the treatment (Days 1-7) and 
recovery weeks (Days 8 -15) a cohort (n=3) of mice were euthanized at intervals throughout the 
protocol.  Control mice soleus and EDL were analyzed on Days 2, 4, 8, and 15, the Anxa6 Vivo-
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morpholino group’s tissue was analyzed on Days 2, 3, 4, and 15, and the Casq1 group’s tissue 
was analyzed on Days 2, 3, and 15.  Initially, tissues from the Vivo-morpholino groups were to 
be analyzed on a similar pattern, as was the Control group; however, due to Vivo-morpholino 
production issues, several mice had to be excluded from analysis.  Protein knockdown was 
measured by western blot as described above.  Additionally, to provide a comparison to the 
low active C3H/HeJ mice Anxa6 and Casq1 expression in soleus from the Vivo-morpholino 
treated animals (treatment day three) and C3H/HeJ mice were analyzed using western blots.  
3.3.3 Statistics   
Physical characteristics were analyzed with an ANOVA to compare strain (C57L/J and 
C3H/HeJ), sex (male and female), weight and percent body fat.  An alpha level of 0.05 was set a 
priori and if a significant main effect was found, a Tukey’s HSD post hoc test was used.  2D-DIGE 
results were analyzed using ANOVA, with significantly differentially expressed protein spot 
determination with an a priori alpha value of 0.05, with subsequent protein identification (mass 
spectroscopy identification) using an a priori alpha value of 0.05.  The conformational western 
blot optical densities (Experiment 1) were analyzed using a Student’s t test (GraphPad Software 
Inc, La Jolla, CA) to compare protein levels between high active and low-active mice with an 
alpha level of 0.05 set a priori.  For the western blot used to analyze Vivo-morpholino results 
(Experiment Two) a 2x2 ANOVA was used to compare day of treatment and treatment group 
with an alpha level of 0.05 set a priori and a Tukey’s HSD post hoc test if main effects were 
significant.  Further comparisons of wheel running with Vivo-morpholino-treatment were 
analyzed using a 3 x 3 ANOVA with week (baseline, treatment, and recovery) and treatment 
group (control, Anxa6 Vivo-Morpholino, and Casq1 Vivo-morpholino) as the main effects.  An 
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alpha level of 0.05 was set a priori.  If a main effect was found significant, a Tukey’s HSD post 
hoc test was used. 
3.4 Results 
3.4.1 Experiment 1: Proteome Determination  
At the time of sacrifice, the male mice in both strains were significantly (p=0.001) 
heavier than the females (C3H/HeJ males 21.25 ± 1.60 g; C3H/HeJ females 18.91 ± 1.06 g; 
C57L/J males 22.21 ± 1.16 g; C57L/J females 17.21 ± 0.92 g).  However, there was no difference 
(p=0.0501) in the percent body fat of the mice between or within strains (C3H/HeJ males 16.54 
± 3.75%; C3H/HeJ females 14.64 ± 1.64%; C57L/J males 13.23 ± 1.92%; C57L/J females 12.62 ± 
1.75%).     
Representative 2D-DIGE gels are depicted in Figure 3.1 and Figure 3.2 for soleus and 
EDL, respectively.  There were 42 differentially expressed proteins identified in the soleus 
(Table 1), with 21 proteins over expressed in high-active animals and 21 over expressed in low-
active animals.  We observed eight differentially expressed proteins in the EDL (Table 2) with 
three proteins over expressed in high-active animals and five over expressed in low-active 
animals.  Of the differentially expressed soleus proteins, the coding genes for 11 are located in 
known physical activity quantitative trait loci (QTL – Table 1) while the coding genes for three 
EDL proteins are located in QTL for physical activity (Table 2).  Table 3 lists the identified 
proteins by their functional relation to muscle contraction.  In general, when examining protein 
differences based on their function, the low active mice exhibited an over expression of 
proteins associated with the electron transport chain and cytoskeletal structure while the high 
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active animals over expressed proteins associated with the Kreb’s (TCA) cycle and calcium 
regulation.   
Anxa6 (p=0.00031) and Casq1 (p=0.000025) were differentially expressed in a highly 
significant manner between the high and low active mice and were categorized as strong 
potential candidates for the peripheral regulation of physical activity due to their role in 
skeletal muscle calcium regulation and thus their expression levels were confirmed by Western 
blot.  Anxa6 was confirmed as significantly over expressed (p=0.01) in both the soleus and EDL 
of the C57L/J mice (Figure 3.3).  Similarly, Casq1 in the soleus of high active mice was a 
confirmed as being significantly more highly expressed (p=0.0024) (Figure 3.4).  
 Co-immunoprecipitation experiments (Table 4) identified one protein associated with 
Anxa6 in both soleus and EDL (alpha S1 casein) of the high-active mice.  Two proteins 
associated with Anxa6 were identified, one in the low-active mice soleus (beta-lactoglobulin) 
and one in the EDL (actin, alpha 1).  Five proteins were associated with Casq1 in the soleus of 
high active mice, including alpha S1 casein (in common with Anxa6).  Three of the Casq1- 
associated proteins in high-active mice (creatine kinase M-type, LIM domain binding 3, troponin 
T3) were also associated with Casq1 in the soleus of low-active mice.  
3.4.2 Experiment 2: Role of Candidate Proteins in Physical Activity   
The Vivo-morpholino treatments were successful in transiently knocking down the 
expression of both Anxa6 and Casq1.  Specifically, in the soleus, both Anxa6 (p=0.0048, Figure 
3.5A) and Casq1 (p=0.0152, Figure 3.5B) were significantly knocked down from baseline.  
Interestingly the control samples over expressed both Anxa6 and Casq1 compared to baseline 
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values during the treatment and recovery weeks.  In the EDL Anxa6 was significantly (p=0.0019) 
knocked down from baseline (Figure 3.6).  However, unlike the soleus there was no difference 
in expression between control baseline protein levels and protein levels during treatment or 
recovery.  EDL Casq1 expression was not analyzed since Casq1 was not expressed differently in 
that tissue between high- and low-active animals (Table 2).  
 When comparing soleus Vivo-morpholino treated samples from Day 3 of treatment to 
C3H/HeJ samples there was no difference in Anxa6 protein expression (Figure 3.7A; p=0.14), i.e. 
the high-active animals had a similar Anxa6 level as the low-active animals when the gene was 
transiently silenced.  However, while Vivo-morpholino did decrease Casq1 levels in the high-
active animals (80% knockdown from baseline), the low-active C3H/HeJ animals had a lower 
expression of Casq1 (Figure 3.7B, p=0.002). 
 The Vivo-morpholino results showed that as expected, there was no difference in 
physical activity response between the treatment groups during the baseline wheel exposures 
(Figure 3.8).  However, during the treatment week, the Anxa6 and Casq1 Vivo-morpholino 
groups ran significantly less than the control group (p=0.001).  At the end of the recovery week, 
activity was similar between all groups.  Interestingly the control group during the treatment 
week and all groups during the recovery week ran significantly (p=0.01) further than the 
corresponding groups during the baseline week (Figure 3.8).  
3.5 Discussion 
The aim of this study was to utilize proteomic and gene-silencing techniques to identify 
skeletal muscle proteins that may be involved in the regulation of physical activity utilizing a 
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high-active versus low-active mouse model.  We observed different protein signature patterns 
in the high- and low-active mice, with the differentially expressed proteins falling into specific 
physiological-function groups depending on the mouse strain.  In general, the high active mice 
over expressed proteins associated with the Kreb’s (TCA) cycle and proteins involved in calcium 
regulation while the low active mice over expressed proteins in the electron transport chain 
and cytoskeletal proteins that influence cell motility and force transduction, suggesting that 
peripheral mechanisms contributing to low-activity and those contributing to high-activity are 
distinct.  Further, when we transiently silenced two of the most differentially expressed 
proteins found in the high-active mice (Anxa6 and Casq1), we observed significant decreases in 
physical activity suggesting that these proteins are involved in regulating physical activity levels.  
While it has been clearly shown that there is a significant genetic influence on physical 
activity regulation5, the site of regulation as well as the specific mechanisms regulating physical 
activity are still ambiguous.  Kelly34 has suggested that both peripheral and central mechanisms 
may be involved in activity regulation; indeed, several studies have considered central brain 
mechanisms focused around the reward pathways, dopaminergic mechanisms44 and 
endocannabinoid mechanisms160.  These central mechanisms have been suggested to provide 
the ‘drive’ to be active.  However, other studies have suggested that without the ‘capability’ to 
be active, an organism will not exhibit high levels of physical activity.  Indeed, Tsao, et  al 51 
showed that a transgenic over expression of Glut4 in skeletal muscle induced a four-fold 
increase in daily activity and Pistilli, et al151 showed that knocking-out IL-15Rα in skeletal muscle 
also increased wheel running activity.  These data, along with Meek, et al’s53 results showing 
that feeding of a higher-fat diet caused selectively-bred high active mice to run further on a 
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daily basis, strongly suggest that skeletal muscle mechanisms can markedly influence the 
amount of physical activity completed, irrespective of central drive.  Thus, this study focused on 
skeletal muscle proteomic differences between high- and low-physically active mice to provide 
foundational targets for further mechanistic studies as well as potential interventions to 
influence physical activity level.  
3.5.1 High-active Animals   
Overall, our results indicated a greater number of differentially expressed proteins in 
the soleus (n=42), as compared to the number of proteins expressed differentially in the EDL 
(n=8) which was not surprising given the markedly greater duration of daily activity that C57L/J 
mice exhibit (avg±SD 351.1±61.6 mins/day) compared to the C3H/HeJ mice (75.6±99.0 
mins/day;12.  In that regard, several protein expression patterns emerged from this study.  In 
particular, the high active C57L/J mice generally over expressed calcium regulatory proteins, 
including Casq1 and Anxa6.  From these results, we would suggest that the high active C57L/J 
mice have an increased capability to be active because their skeletal muscles can more 
efficiently release and take up calcium due to the relative over expression of these calcium 
regulatory proteins.  Casq1 is a calcium binding protein located in the sarcoplasmic reticulum 
(SR)69 while Anxa6 influences calcium release from the SR57 by increasing the open probability 
time of the calcium channel60,161.  While Casq1 is located in the SR, Anxa6 is localized around 
individual myofibrils and is associated with the terminal cisternae of the SR membrane57.  
Further, the Anxa6 gene is located in a previously identified QTL for the “mini muscle” 
phenotype, which leads to an increased force production from the triceps surae of mice 
selectively bred for high physical activity14.  Thus, the over expression of both Casq1 and Anxa6, 
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in conjunction with their biological roles, could form a potential mechanism by which high-
active mice exhibit decreased fatigability of skeletal muscle and an increase in force production 
resulting in an increased capability to do physical activity (Figure 3.9).   
It has been shown that there is an inverse relationship between skeletal muscle force 
production and skeletal muscle fatigue resistance162 due in large part to calcium concentration 
during excitation coupling162,163.  A higher level of Anxa6 in the high-active animals would result 
in a higher concentration of calcium released from the SR, which would cause greater force 
production164.  However, this higher myoplasmic calcium concentration following contraction 
would actually increase the fatigability of skeletal muscle162,164.  Offsetting this potential 
increase in fatigability with Anxa6, Casq1’s calcium-binding properties in the SR69, would lead to 
an increased binding of calcium following the Anxa6-induced increased release of calcium from 
the SR.  Thus, Casq1 would act to decrease myoplasmic calcium levels and thereby reduce 
fatigability.  In fact, the lower the myoplasmic calcium level following contraction results in a 
fatigue resistant phenotype of skeletal muscle165.  The interplay between increased levels of 
Anxa6 and Casq1 would theoretically lead to both an increase in force production and a 
decreased fatigability of the skeletal muscle, especially in the slow-twitch fiber dominated 
soleus tissue154.  A decreased fatigability – especially of slow-twitch fibers - could conceptually 
increase duration of activity, while an increased force production in both slow- and fast-twitch 
fibers would increase speed of activity.  Supporting this hypothesis is previous work from our 
lab has shown that the high-active C57L/J – which we used in this study - run significantly 
farther (892%), longer (464%) and faster (228%) than the low-active C3H/HeJ on a daily basis12.  
Additional support for the role of calcium regulation in increasing physical activity comes from 
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our observations of over expression in the high active mice of Annexin A4 and Sarcalumenin, 
which are involved in calcium regulation and force production. 
 As a means to confirm the hypothesis of Anxa6 and Casq1 influencing calcium 
homeostasis and resultant physical activity level, we used transient gene silencing to 
knockdown both proteins in high active C57L/J mice.  Our hypothesis of the role of Anxa6 and 
Casq1 levels in regulating physical activity was supported by our observations that with 
knockdown of either Anxa6 or Casq1, there was a significant reduction in wheel running (Figure 
3.8).  Further, to confirm that calcium regulation in skeletal muscle was not impaired by 
knockout of Anxa6 or Casq1, we compared Anxa6 and Casq1 between Vivo-morpholino treated 
animals and the low-active C3H/HeJ animals.  We observed that with knockdown, Anxa6 levels 
were similar between high- and low-active animals (Figure 3.7A).  Casq1, while decreased from 
the normal state, was still higher in the treated animals versus the low-active animals (Figure 
3.7B).  Thus, while protein knock down decreased activity in the high-active mice - Anxa6 Vivo-
morpholino mice ran a distance of 1.37 ± 0.85 km/day and the Casq1 Vivo-morpholino group 
ran 1.36 ± 0.02 km/day,  from the control average of 10.01 ± 1.10 km/day - these distances 
were still higher than typical low-active C3H/HeJ  male mice (0.6 ± 1.1 km)12.  Thus, the Vivo-
morpholino treatments did not knock down Anxa6 and Casq1 completely below C3H/HeJ levels, 
but still significantly decreased protein expression and decreased physical activity.  
Interestingly during the treatment week, the control animals exhibited a significant 
increase in physical activity compared to baseline (Figure 3.8).  This increased activity 
corresponded to an increase in Anxa6 (Figure 3.5A) and Casq1 (Figure 3.5B) in the soleus.  Yang 
et al17 observed that when a running wheel is returned after it has been removed – which was 
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the case in our study - there is an increase in physical activity level.  Yang et al16,17 speculated 
that the increased activity after having no wheel was a result of increased action in the reward 
driven behavior system of the brain17.  In fact we have shown in previous studies that an 
increase in expression of Vesicular monoamine transporter 2 (Vmat2) leads to an increase in 
wheel running150.  Vmat2 stores dopamine in synaptic vesicles and has been suggested to be 
associated with reward driven behavior45.  We would hypothesize that in addition to Yang’s 
suggested mechanism and the action of Vmat2, the increase in physical activity could also be a 
result of our observation of the over expression of Anxa6 and Casq1 in the control animals’ 
soleus.  Additionally in the soleus, Anxa6 and Casq1 returned to baseline levels, which could 
have resulted in the increase in wheel running seen in the recovery week.  
Results from the CoIP in the high active mouse tissues – especially the soleus - further 
support our hypothesis of an altered calcium-regulation affecting physical activity.  Casq1 is 
permissive in a network formed by several proteins we identified in the CoIP (Troponin 3, 
desmin, creatine kinase M, and LIM domain binding 3) in both mice and humans157.  Thus, we 
would suggest that an increase in Casq1 would increase the activity of this network which 
would further increase muscle contractile state and contribute to the regulation of physical 
activity level in the high-active animals.  
Potential functional roles for some of the proteins identified with the CoIP are not as 
clear.  For example, both Anxa6 and Casq1 in the high active animals are associated with alpha 
S1 casein in both the soleus and EDL tissues.  There is little information regarding the role of 
alpha S1 casein in skeletal muscle.  However, alpha S1 casein does influence the transport of 
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calcium phosphate from the endoplasmic reticulum166 suggesting a potential  functional linkage 
with calcium-regulation and physical activity response.  
 In addition to calcium regulation, enhanced Krebs (TCA) Cycle activity could positively 
affect maintenance of high physical activity.  The high active C57L/J animals over expressed 
several proteins associated with the Kreb’s(TCA) cycle, with the most significant being an over 
expression of three proteins in the pyruvate dehydrogenase complex (i.e. pyruvate 
dehydrogenase protein X component, pyruvate dehydrogenase [acetyl-transferring]-
phosphatase 1, and pyruvate dehydrogenase E1 component subunit beta).  The over expression 
of the subunits of pyruvate dehydrogenase could conceptually lead to an increased capability 
to convert pyruvate to acetyl-CoA, with a potential subsequent increase in Kreb’s (TCA) cycle 
activity and an increased NADH and FADH availability167.  This process would increase available 
ATP to meet the demands of an increased physical activity level.   
In support of a potential increased Kreb’s (TCA) cycle capability in the high-active mice, 
was an over expression of the key Kreb’s (TCA) regulator dihydrolipoyllysine-residue 
succinyltransferase component of the 2-oxoglutarate dehydrogenase complex168.  The 
oxoglutarate dehydrogenase complex primarily controls the production of Succinyl-COA; an 
over expression of the dihydrolipoyllysine-residue succinyltransferase component would 
increase the capability to produce both succinyl-COA as well as increased levels of both NADH 
and FADH168.  Further, the coding gene for dihydrolipoyllysine-residue succinyltransferase 
component is located in identified QTL associated with both wheel running distance12 and the 
mini muscle14.  In addition to the hypothesis that increased Kreb’s (TCA) cycle activity supports 
higher activity is that apolipoprotein A-1 (Apo1) was identified in the soleus and EDL of high 
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active mice.  Apo1 is associated with cholesterol and fat storage, and in skeletal muscle, Apo1 
could facilitate the use of fat as an additional substrate source for the Kreb’s (TCA) cycle169.  
This suggestion is supported by Meek et al53 who showed that mice bred for high activity 
increase their activity level when fed a high fat diet.  Thus, an over expression of Apo1 and 
proteins associated with the Kreb’s (TCA) cycle could contribute to the high wheel running 
activity of the C57L/J mice by increasing NADH and FADH production, which would meet the 
energy demands for high physical activity.  The higher efficiency of the TCA cycle combined 
with an increased usage of fat, decreased fatigability and increased force production due to the 
over expression of calcium-regulating proteins, would lead to the high-active animals having an 
increased capability of sustaining activity. 
3.5.2 Low-active Animals   
While we observed several protein expression patterns that would support high-activity 
in those mice that have inherently higher-activity patterns, there were also protein expression 
patterns in the low-active animals that could conceptually inhibit activity (Figure 3.10).  The low 
active animals over expressed the enzyme 6-phosphofructo-2 kinase/fructose-2, 6-
biphosphatase 1 which decreases the activity of the primary regulator of glycolysis, 
phosphofructokinase 1170.  An over expression of 6-phosphofructo-2 kinase/fructose-2, 6-
biphosphatase 1 would lead to a higher level of degradation of 2,6-bisphosphate which would 
subsequently decrease glycolysis and increase gluconeogenesis170.  The decrease in glycolysis 
would decrease the generation of pyruvate and acetyl-CoA, thereby leading to a decrease in 
electron donors for the electron transport chain (ETC) and a potential decrease in available 
energy needed to support activity.  
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Interestingly, we also observed that the C3H/HeJ mice over expressed proteins 
associated with the ETC (e.g. electron transfer flavoprotein ubiquinone oxidoreductase, ATPase, 
and NADH dehydrogenase [ubiquinone]).  The over expression of these proteins would 
generally lead to a more efficient generation of ATP via the electron transport chain171.  We 
would speculate that in the low active animals a more efficient generation of ATP through the 
ETC could serve as a compensatory mechanism for the inhibited glycolytic production of 
electron donors as well as the relative under expression of proteins in the Kreb’s (TCA) cycle as 
compared to the high-active animals.  
In addition to the metabolic proteins, the C3H/HeJ animals over expressed proteins 
associated with cytoskeletal structure, specifically radixin, Lumican, tubulin beta 3, coflin 2, 
alpha actinin 2, and tubulin 8.  These proteins bind actin and microtubules to influence cell 
membrane/cytoskeletal organization172-175.  The over expression of these proteins suggest that 
there is increased rigidity of the muscle cells resulting in an overall decreased motility of the 
C3H/HeJ skeletal muscle fiber as compared to the C57L/J mice176.  Peng, et al176 suggested that 
the decreased motility of the cell can decrease force transduction and skeletal muscle force 
production.  Thus, the over expression of these cytoskeletal structural proteins, as well as the 
observed over expression of the specific glycolytic and ETC proteins could theoretically hinder 
the capability for wheel running and physical activity.  These proteins are attractive targets for 
further Vivo-morpholino studies investigating whether the knockdown of these proteins could 
increase the activity of the low-active animals.  
 While our results provide attractive potential peripheral mechanisms for further study, 
there is a limitation that should be considered.  It is possible that not all proteins differentially 
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expressed between high- and low-active animals were detected in this study.  However, this is 
the first study to investigate the peripheral proteomic regulation of physical activity and given 
that 2D-DIGE is currently considered one of the most sensitive methods for an initial global 
protein scan89, it is probable that we detected the majority of differentially expressed proteins 
associated with the inherent high- and low-activity states in these mouse strains.  As such, 
these results can be used as a foundation for future research using more specific protein 
methodologies to discover other proteins associated with activity level, as well as providing a 
target list for further gene-silencing studies.  
In conclusion, our results support the hypothesis that peripheral, skeletal muscle 
factors that participate in the regulation of voluntary physical activity arise from multiple 
protein pathways.  Specifically, there appears to be different mechanism regulating high versus 
low activity.  High active animals over expressed proteins associated with the Kreb’s (TCA) cycle 
and calcium regulation suggesting a decreased fatigability, increased force production, and 
increased capability of providing substrates for the electron transport chain.  We confirmed the 
role of two calcium-handling proteins in regulating activity by transiently knocking down the 
proteins in healthy animals with a subsequent reduction in activity.  Conversely, low-active 
animals over expressed structural proteins that could decrease muscle fiber motility, as well as 
over expressing proteins that would decrease glycolysis with a potential compensation through 
an increased efficiency of the electron transport chain.  Future studies should focus on 
confirming these proteins’ roles in the low-activity state.  Maybe most importantly, given the 
potentially different peripheral regulating mechanisms in the high- and low-active mice, 
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conclusions regarding causal mechanisms of low-activity cannot be inferred from results on 
high-active animals and vice-versa. 
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CHAPTER IV 
LESSONS LEARNED FROM VIVO-MORPHOLINOS: HOW TO AVOID VIVO-MORPHOLINO 
TOXICITY 
4.1 Synopsis 
 Vivo-morpholinos are oligonucleotide analogs that transiently silence genes by blocking 
translation or splicing of pre mRNA.  Vivo-morpholinos are a promising tool in that there has 
been little to no toxicity reported with the treatment.  However, in a recent study conducted in 
our lab, we observed that treatment with Vivo-morpholinos resulted in high mortality rates.  
Cause of death was the result of oligonucleotide hybridization resulting in clustering of the 
dendrimer delivery moiety of the Vivo-morpholino.  The dendrimer clusters increased blood 
viscosity and caused cardiac arrest.  Therefore, in order to achieve the gene silencing benefits 
of Vivo-morpholinos, the base pairing potential of the oligonucleotide analogs should be 
considered when designing experiments.  
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4.2 Introduction 
The ability to silence genes in vivo provides the opportunity to identify gene function 
and could serve as a treatment for a variety of genetic disorders.  Attempts to develop tools to 
silence genes in vivo have resulted in limited success.  Initially, siRNA and phosphorodiamidate 
morpholino oligomers (PMOs) were thought to be potential methodologies for in vivo gene 
silencing; however, their use resulted in limited gene silencing and associated toxicity99.   
Morcos et al100 developed Vivo-morpholinos as an alternative to siRNA and PMOS.  Vivo-
morpholinos are anti-sense oligonucleotide analogs that bind to complementary RNA 
sequences and block translation of a targeted gene100.  Vivo-morpholinos are unique in that the 
delivery moiety consists of eight guanidinium head groups (dendrimer) of arginine-rich 
peptides, thus allowing for resistance to proteases and nucleases to prevent degradation and 
increase the efficiency of uptake into the cell by endocytosis100.          
 To date there are twenty-eight studies using Vivo-morpholinos100-126,150 and all have 
reported at least 50% knockdown of the target gene with no adverse side effects.  Fifteen of 
these studies used a mouse model100,101,103,110,112,114,119,121-127,150 with the remaining studies using 
rats115-117,  newts120, chicken embryos106, zebrafish102,104,105  and amphibians107,109,118.  In the 
mouse model, it has been shown that Intravenous (IV) or intraperitoneal (IP) administration 
Vivo-morpholinos were equally efficacious, and recent studies have shown success with direct 
injection in target tissue115-117.  To this point, no toxicity of Vivo-morpholinos has been reported.  
 Our lab has evaluated the gene silencing ability and washout effects of Vivo-
morpholinos in various tissues150.  We have published the effects of three different Vivo-
morpholinos in addition to a Vivo-morpholino cocktail (combination of two Vivo-morpholinos) 
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and achieved significant knockdown of the targeted proteins (Drd1, Glut4, Vmat2) and 
observed no adverse side effects even when using with the Vivo-morpholino cocktail150.  
 Recently, we initiated a study with the goal of using Vivo-morpholinos to silence 
Annexin A6 (Anxa6) and Calsequestrin 1 (Casq1), both genes being involved in skeletal muscle 
calcium regulation, via IV injection in the mouse model.  In addition to these single Vivo-
morpholino treatments, we combined the Anxa6 and Casq1 Vivo-morpholinos in a cocktail in 
an attempt to silence both genes at the same time to determine the effect on physical activity.  
The initial results were disconcerting in that the treatments resulted in numerous fatalities.  
Thus, the purpose of this report is to characterize the cause of death, mechanism of action, and 
propose possible solutions to the toxicity we observed with Vivo-morpholinos in this model.  
4.3 Observation of the Problem 
 Vivo-morpholinos were obtained from GeneTools LLC (Philomath, OR) targeting Anxa6 
and Casq1 in 2000 nmol batches.  GeneTools LLC provides a Vivo-morpholino design service 
whereby the investigator provides the gene of interest along with the NCBI accession number.  
GeneTools LLC then generates Vivo-morpholinos for the targeted genes.  Previous work from 
our lab has utilized the 400 nmol batch of Vivo-morpholinos due to the smaller sample sizes of 
our studies150.  Given that our research focus is on the genetic mechanisms regulating daily 
physical activity, we used previously phenotyped high-active C57L/J mice12 (The Jackson 
Laboratory, Bar Harbor, ME) and gave them a tail vein injection of Vivo-morpholinos (11mg/kg 
or ~56 ul of Anxa6 or Casq1 Vivo-morpholino) or a cocktail treatment (11mg/kg of each Vivo-
morpholino or ~112 ul).  These dosages have been recommended by GeneTools100 and used in 
the literature136 without toxicity.  Following the injections, the mice appeared to recover and 
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were ambulatory within the cage for 1-2 minutes, followed by an immediate loss of 
consciousness, an increased breathing rate, and fluid leakage from the nose.  Once mice 
displayed these signs of distress, mice were placed on heating pads (37o C) and given 
supplemental oxygen (via nose cone).  Unfortunately, once the mouse lost consciousness, we 
observed in all cases that death occurred within five minutes.  By the time the solution to the 
problem was determined (detailed below) and after using several potential solutions provided 
by the company, a total of 14 out of 17 (82%) animals receiving the Vivo-morpholino cocktail 
died, while 6 out of 9 (66%) of the Casq1 Vivo-morpholino died and 2 out of 8 (25%) animals 
receiving the Anxa6 Vivo-morpholino died.  None of the 15 control animals (saline injection) 
had a fatality.  
 These observations were disconcerting for several reasons, including financial, 
logistical, scientific, but most importantly, the trauma placed on the animals.  While all 
measures were taken to insure humane treatment of the animals (and all studies had been 
approved by our IACUC), the Vivo-morpholino treatment resulted in unnecessary stress placed 
on the mice prior to death.  As noted earlier, there has been no previous evidence indicating 
the observed fatalities seen in our study.  Thus, for further use as a laboratory tool and given 
that potential future applications for Vivo-morpholino may include both non-human 
primates115 and human clinical trials123 it is critical that the cause of the Vivo-morpholino 
toxicity in this study be understood to prevent future fatalities associated with Vivo-morpholino 
treatment.  
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4.4 Potential Solutions to the Problem Provided by GeneTools 
 Following the fatalities associated with Vivo-morpholinos, GeneTools LLC, was 
consulted.  GeneTools acknowledged that they were aware of similar fatalities associated with 
Vivo-morpholino treatment; however, GeneTools was unaware of the mechanism of action that 
caused the increased mortality rates.  GeneTools hypothesized that the fatalities were a result 
of guanidinium toxicity and recommended treatment with lower dosages even though we had 
previously used the recommended dosages without incident150.  Therefore, we subsequently 
injected C57L/J mice with Vivo-morpholino treatment of Casq1, Anxa6, and cocktail at a dosage 
of 4mg/kg (reduced from normal dose of 11 mg/kg).  This treatment resulted in 8 out of 8 
(100%) fatalities in the cocktail group, along with 3 out of 7 (43%) fatalities in the Casq1 group 
and 1 out of 6 (17%) fatalities in the Anxa6 group.  Thus, by markedly reducing the dose, we 
eliminated the possibility that guanidinium toxicity was the causal factor.  Supporting this 
conclusion is much older literature that reports that the fatal dose of guanidinium is actually 30 
times more than the amount the mice received with any of the Vivo-morpholino treatments177.   
Further, as we have noted earlier, neither we nor others have observed fatalities with a Vivo-
morpholino dosage of 11mg/kg122,136,150.  Thus, guanidinium toxicity was ruled out as the cause 
of death.  
4.5 Investigation into the Cause of Death   
 In order to determine the cause of death, mice that died were immediately necropsied 
with brain, heart, lung, liver, spleen, large intestine, soleus, gastrocnemius, extensor digitorum 
longus, and kidneys removed.  Two initial observations were made during necropsy that set 
these animals apart from normal anatomical findings during routine dissections: 1) the 
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deceased animals’ eyes had a cloudy opaque appearance (Figure 4.1 Panel A); and 2) there was 
necrotic tissue in the left ventricle (Figure 4.1 Panel B) of the heart with an increased blood 
thickness in the vena cava and aorta.  These observations were common across all animals that 
died after Vivo-morpholino treatment.  These observations have not been previously 
documented nor have we observed these symptoms in our previous Vivo-morpholino studies.  
Interestingly, one of our previous studies133 used the Casq1 Vivo-morpholino (ordered 400 
nmol batch) and did not result in increased mortality rates of the mice.  Thus, we initially 
hypothesized that the mechanism of action for mortality was due to an unknown uniqueness of 
the synthesis of the 2000 nmol product.  
 Using standard techniques178, we evaluated the Casq1 Vivo-morpholino at 2000 and 
400 nmol concentrations via Matrix Assisted laser desorption/ionization time of flight (MALDI-
TOF) with sinapinic acid as the matrix in an effort to identify any potential contaminants in the 
2000 nmol Vivo-morpholino.  We observed no difference in the spectra between the 2000 or 
400 nmol Casq1 Vivo-morpholinos (Figure 4.2).  Furthermore, the spectra were not different 
from the spectra provided by GeneTools in the quality control report.  
 With the potential of contamination eliminated, we revisited the necropsy results, 
especially the necrosis of the left ventricle and increased blood thickness in the vena cava and 
aorta.  Given these observations, we hypothesized that Vivo-morpholinos caused significant 
blood clotting in the heart and vessels, resulting in markedly decreased oxygen delivery to the 
heart and subsequent myocardial infarction.  
 To initially evaluate this hypothesis, a test of the effects of Vivo-morpholinos on blood 
clotting was conducted.  A C57L/J mouse that had not received Vivo-morpholinos was 
 
 
76 
 
anesthetized with isoflurane and blood was removed by cardiac puncture.  The mouse was then 
euthanized using cervical dislocation.  Three blood droplets consisting of 100 ul of whole blood 
were aliquoted on a microscope slide.  Each blood droplet was mixed with either 10 ul of saline, 
10 ul of Casq1 Vivo-morpholino or 10 ul of the Vivo-morpholino cocktail.  The blood droplets 
were then monitored using a dissecting microscope (Olympus, Center Valley Pennsylvania) with 
clotting time evaluated by the amount of time it took for a lattice-like structure to form around 
the outer ring of the blood droplet.  To ensure objectivity, the technician performing the 
evaluation was blinded to the treatment groups.  The results showed that treatment with the 
Casq1 Vivo-morpholino decreased clotting time by 21% and treatment with the Vivo-
morpholino cocktail further decreased clotting time by 59% as compared to the saline control 
(Figure 4.3).  Thus, treatment with Vivo-morpholino caused significant clotting suggesting that 
Vivo-morpholino treatment (and especially the cocktail treatment) resulted in blood clot 
formation that resulted in cardiac death. 
4.6 Suggested Mechanism for Blood Clot Formation and Cardiac Death 
 With our results of a reduced clotting time with Vivo-morpholino treatment and the 
increased blood viscosity observed in the Vivo-morpholino-treated animals, we hypothesized 
that the structure of the Vivo-morpholino was leading to a significantly enhanced blood clot 
formation.  Due to the fact that the majority of the fatalities occurred in the cocktail treatment 
group, we examined the sequences of the Casq1 and Anxa6 Vivo-morpholino.  As noted earlier, 
the sequences chosen for the oligo-portion of the Vivo-morpholino are generally chosen by 
GeneTools (as was the case in our previous studies), but there is an option for the client to 
provide the oligo-sequences.  When examining the sequences of the supplied Casq1 and Anxa6 
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Vivo-morpholino, we noted that there were nine nucleotide bases that could hybridize when 
the sequence was arranged by aligning the 3’ and 5’ ends (Figure 4.4).  Furthermore, there 
were four potential nucleotide-hybridizing pairs in the Casq1 Vivo-morpholino and three in the 
Anxa6 Vivo-morpholino (Figure 4.4).  In checking the previous Vivo-morpholino we had used in 
our non-fatal experiments150, we found that the oligos we employed did not have 5’ to 3’ base 
pairing/hybridization.  Thus, we would suggest that as the Vivo-morpholinos hybridized, 
especially in the cocktail treatments, this hybridization formed a complex consisting of the 
hybridized Vivo-morpholino as well as the delivery moiety (dendrimer).  This  dendrimer cluster 
probably was responsible for the observed increased blood viscosity179 which likely led to an 
ischemia state of the heart with a resulting fatality180. 
 The hypothesized mechanism by which the dendrimer cluster induced fatality is based 
on the work by Roberts et al181 who investigated the toxic effects associated with dendrimer 
administration in vivo.  Specifically, Roberts et al181 examined the effects of dendrimer 
generations on in vivo function.  The results showed that the higher generation of dendrimers 
(over 10,000 Daltons) had an effect on red blood cell aggregation181.  The increased number of 
cationic dendrimer head groups associated with the higher generation level altered the surface 
charge density of the membranes of the red blood cells.  This caused a conformational change 
in the membrane of the red blood cells resulting in sedimentation of the red blood cells181,182.  
The sedimentation of red blood cells caused increased blood viscosity and blood clotting which 
led to myocardial infarction180. 
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4.7 Solution to Fatal Vivo-morpholinos 
 The easiest solution to the toxicity issue appears to be care taken when designing the 
Vivo-morpholinos to insure little to no hybridization possibility.  GeneTools allows customers to 
design their own oligos and we would recommend this option.  However, there are situations 
such as ours, where targeted genes may have similar sequences.  While we would recommend 
that wherever possible to use careful oligo design, one potential solution to alleviate the 
dendrimer clustering if the oligo shows a potential for hybridization is by adding an equal 
volume of physiological saline to the Vivo-morpholino injection and vortexing vigorously before 
injection.  When we employed this simple procedure, we eliminated fatalities in the mice that 
received these treatments (n=6), yet still observed significant gene silencing.  The addition of 
physiological saline is thought to prevent red blood cell aggregation by preserving the surface 
charge density of the red blood cells, which is accomplished by the Cl- present in the 
physiological saline. 
In conclusion, while Vivo-morpholinos are an ideal tool for transient gene silencing, 
caution should be taken in oligo design to avoid dendrimer cluster formation and resultant 
increased blood viscosity.  In order to prevent fatalities it is recommended that the 
oligonucleotide analogs be analyzed for potential 3’ to 5’ base pair hybridization in order to 
prevent clustering of dendrimers.   
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CHAPTER V  
CONCLUSIONS 
 Physical activity is correlated to decreased rates of cardiovascular disease, obesity, type 
II diabetes and some types of cancer.  While there is strong evidence that genetic factors 
account for most of the influence on physical activity regulation, little is known about how 
these factors contribute to physical activity regulation.  The studies in this dissertation aimed to 
evaluate the use of the novel gene silencing tool, Vivo-morpholinos in the physical activity 
mouse model, to identify proteomic differences between high and low physically active mice, 
and to use Vivo-morpholinos to transiently silence identified proteins.  
 The results showed that Vivo-morpholinos are an effective tool for gene silencing in 
skeletal muscle and that in order to achieve gene silencing in the brain, the bradykinin analog 
RMP-7 is required with treatment.  However, caution should be taken when designing Vivo-
morpholinos to avoid hybridization.  It is further recommended that equal volume of 
physiological saline be mixed with Vivo-morpholinos in order to prevent the possibility of 
hybridization. 
 The identification of proteins associated with high physical activity were proteins 
associated with calcium regulation and Kreb’s (TCA) cycle while there was an over expression in 
the low active mice of ETC and structural proteins.  Annexin A6 and Calsequestrin 1, both over-
expressed in high-active mice and were selected for further evaluation for their involvement in 
physical activity regulation.  The results showed that with a transient knock down of Annexin 
A6 and Calsequestrin 1 there was a significant reduction in physical activity.  Moreover, the 
over expression of both proteins led to an increase in physical activity level.  The results of this 
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dissertation show that there are peripheral components regulating physical activity and that 
further investigations into the regulation of physical activity must include a gene silencing 
approach to evaluate cause and affect mechanisms.  
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APPENDIX A: 
 FIGURES 
II Vivo-morpholinos induced transient knockdown of physical activity related proteins 
 
Figure 2.1: Experiment 1, Vmat2 protein level in the nucleus accumbens. 
 Mean ± standard deviation of western blot optical band density and a representative western 
blot comparing Saline, Scramble, and Vivo-morpholino treated animals for Vmat2 protein 
expression in the nucleus accumbens of the brain.  There was no difference between the 
treatment groups at four (p=0.87, Panel A) or eleven (p=0.14, Panel B) days post treatment.   
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Figure 2.2: Experiment 1, Vmat2 protein level in the soleus. 
 Mean ± standard deviation of western blot optical band density and a representative western 
blot comparing Saline, Scramble, and Vivo-morpholino treated animals for Vmat2 protein 
expression in the soleus.  Panel A shows Vmat2 expression at four days post-last injection.  
There was a significant decrease (p=0.04) in Vivo-morpholino treated animals compared to 
Saline and Scramble treated animals in Vmat2 expression at four days post injection.  Panel B 
shows Vmat2 expression at eleven days post-last injection.  There was a significant increase 
(p=0.03) in Vivo-morpholino treated animals compared to Saline and Scramble treated animals 
in Vmat2 expression at eleven days post injection. 
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Figure 2.3: Experiment 1, mouse wheel running. 
Average daily distance ran for the baseline, injection, and recovery week for animals treated 
with saline, Vivo-morpholino vehicle only (scramble) and the Vivo-morpholino targeting Vmat2 
(Vmat2).  Vmat2 group significantly (*p=0.001) increased activity in the recovery week 
compared to the baseline and injection week.  There was no difference in physical activity 
(p>0.05) in the scramble or saline treated animals for baseline, injection, and recovery weeks.   
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Figure 2.4: Experiment 2, Evaluation of the washout time course of Vivo-morpholinos targeting 
Vmat2. 
Panels A, B, and C represent soleus samples while panels D, E, and F represent nucleus 
accumbens samples.  Panel A represents western blot data probing for Vmat2 in the soleus for 
both unlocked wheel and locked wheel groups.  Panel B is the optical density of the individual 
western blot bands from panel A.  A nonlinear regression was run on the data in panel B which 
generated an R2=0.65 for the animals on unlocked wheels and an R2=0.55 for animals on locked 
wheels.  Given there was no difference (p=0.42) in the slope or y intercept of the unlocked 
wheel and locked wheel groups, the data were pooled at each Day (Panel C).  Panel C shows 
that there was a significant knockdown (+p=0.001) in Vmat2 on days 2-6 and a significant 
(*p=0.001) over expression in Vmat2 on day 9 in the soleus.  The same methodologies were 
applied to Panels D, E, and F for the nucleus accumbens.  The nonlinear regression resulted in 
R2=0.99 for the unlocked wheel group and R2=0.99 for the locked wheel group, and there was 
no difference (p=0.66) in the slope and y intercepts of the lines in panel E.  Additionally Vmat2 
was only significantly knocked down on Days 5 and 6 (+p=0.001) with a significant over 
expression (*p=0.001) on Day 11.  The mouse in the locked wheel group representing data for 
Day 11 was removed from analysis because it developed malocclusion in the front incisors and 
became malnourished, thus altering physical activity level.  
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Figure 2.5: Experiment 2, α-synuclein protein level in nucleus accumbens. 
Western blot analysis probing for α-synuclein to confirm the signal for the over expression of 
Vmat2 protein seen in the nucleus accumbens.  There was an increase in α-synuclein at days 2 
and 7-10.  α-synuclein is an indicator of Vmat2 transcription thus when Vmat2 was knocked 
down by the Vivo-morpholino there was an increased stimulus placed on the cell to transcribe 
more Vmat2. 
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Figure 2.6: Experiment 2, mouse wheel running. 
Average daily distance ran for animals treated with Vivo-morpholino targeting Vmat2 for the 
baseline week, injection week (Days 1-5), and recovery week (Days 6-10) of washout protocol.  
Physical activity was significantly (*p=0.0016) increased in Days 6-10. 
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Figure 2.7: Experiment 3, Drd1 and Glut4 protein level. 
Western blot and mean ± standard deviation of optical densities of soleus tissue that 
underwent the Vivo-morpholino cocktail treatment.  Panel A represents four days post 
treatment of Drd1 and Glut4 expression comparing controls to Vivo-morpholino cocktail 
treated animals.  There was a significant knockdown for both Drd1 (p=0.01) and Glut4 (p=0.04).  
Panel B represents eleven days post treatment of Vivo-morpholino cocktail.  There was no 
difference between control and Drd1 (p=0.79) and Glut4 (p=0.58) expression.  
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Figure 2.8: Experiment 3, mouse wheel running. 
Average daily distance ran for baseline, injection, and recovery week for animals treated saline 
(control) and the morpholino cocktail targeting Drd1 and Glut4 (Vivo-morpholino).  There was 
no difference (p=0.15) between the activity of the control group and the morpholino group. 
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Figure 2.9: Experiment 3, Drd5 and Glut1 protein level. 
Western blot and mean ± standard deviation of optical densities of soleus tissue that 
underwent the Vivo-morpholino cocktail treatment.  Panel A represents four days post 
treatment of Drd5 and Glut1 protein expression comparing controls to Vivo-morpholino 
cocktail treated animals.  There was not a significant knockdown for either Drd5 (p=0.22) or 
Glut1 (p=0.56).  Panel B represents eleven days post treatment of Vivo-morpholino cocktail.  
There was no difference between control and Drd5 (p=0.93) and Glut1 (p=0.36) expression.   
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III The Differential Skeletal Muscle Proteome in High and Low Active mice 
 
Figure 3.1: Representative 2D gel of soleus skeletal muscle (chosen as the “pick” gel by 
DeCyder) 
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Figure 3.2: Representative 2D gel of extensor digitorum longus (EDL) skeletal muscle (chosen as 
the “pick” gel by DeCyder) 
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Figure 3.3:  Mean ± standard deviation of confirmatory western blots for Annexin A6 in high 
active (C57L/J) mice and low active (C3H/HeJ) mice for soleus and EDL tissue.  The optical 
density of the blot is represented as mean ± standard deviation along with a representative 
blot.  The high active animals significantly (p=0.01) over expressed Annexin A6 in the soleus and 
EDL.  
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Figure 3.4:  Mean ± standard deviation confirmatory western blots for Calsequestrin 1 in high 
active (C57L/J) mice and low active (C3H/HeJ) mice.  The optical density of the blot is 
represented as mean ± standard deviation along with a representative blot.  The high active 
animals significantly (p=0.0024) over expressed Calsequestrin 1 in the soleus.  
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Figure 3.5: Panel A: Mean ± standard deviation.  Western blot data and a representative 
western blot image for Annexin A6 expression in the soleus for control and Annexin A6 Vivo-
morpholino treated animals.  There was a significant (*p=0.0048) decrease from baseline in the 
Annexin A6 protein expression in the Vivo-morpholino group and an increase in Annexin A6 
protein expression in the control group from baseline.  Panel B: Western blot data and a 
representative western blot image for Calsequestrin 1 expression in the soleus for control and 
Calsequestrin 1 Vivo-morpholino treated animals.  There was a significant (*p=0.0152) decrease 
from baseline in the Calsequestrin 1 protein expression in the Vivo-morpholino group and an 
increase in Calsequestrin 1 protein expression in the control group from baseline. 
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Figure 3.6: Mean ± standard deviation.  Western blot data and a representative western blot 
images for Annexin A6 expression in the EDL for control and Calsequestrin 1 Vivo-morpholino 
treated animals.  There was a significant (*p=0.0019) decrease from baseline in the Annexin A6 
protein expression in the Vivo-morpholino group. 
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Figure 3.7:  Panel A:  Mean ± standard deviation.  Western blot data and a representative 
western blot image for Annexin A6 expression in the soleus of C3H/HeJ mice and Annexin A6 
Vivo-morpholino treated animals on Day 3 of treatment.  There was no difference in Annexin 
A6 protein expression (p=0.14).  Panel B: Western blot data and a representative western blot 
image for Calsequestrin 1 expression in the soleus of C3H/HeJ mice and Calsequestrin 1 Vivo-
morpholino treated animals on Day 3 of treatment.  C3H/HeJ mice had significantly (*p=0.002) 
less Calsequestrin 1 than Vivo-morpholino treated animals.  
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Figure 3.8: Mean ± standard deviation.  Physical activity responses (Average km ran per day) of 
C57L/J mice receiving Vivo-morpholino treatment knocking down Annexin A6 or Calsequestrin 
1.  There was a significant decrease (*p=0.001) in activity for the Annexin A6 and Calsequestrin 
1 Vivo-morpholino treated animals.  Additionally there was a significant (+p=0.01) increase in 
activity in the control group during the treatment week and all groups in the recovery week as 
compared to baseline.  
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Figure 3.9: Proposed schema of peripheral skeletal muscle protein mechanisms increasing 
capability for physical activity in high-active animals.  1: As calcium levels rise during EC 
coupling Annexin A6 binds to the RyR increasing the open probability time, thereby releasing 
more calcium.  2: Calcium binds to troponin C allowing for actin myosin cross bridge formation.  
The higher concentration of calcium results in high force production and fatigability.  3: Energy 
in the form of ATP is generated by the Kreb’s (TCA) cycle and Electron Transport Chain (ETC).  A 
higher amount of proteins in the pyruvate dehydrogenase complex leads to high Acetyl CoA 
levels which results in more turns of the Kreb’s (TCA) cycle.  4: This leads to more NADH and 
FADH, which yields more ATP from the ETC chain.  5: Following contraction there is elevated 
calcium in the myoplasm, which causes fatigue.  6: Increased levels of calsequestrin 1 bind free 
calcium and store it in the sarcoplasmic reticulum, thereby reducing fatigability.  The 
combination of increased forced production, increased substrate availability by the Kreb’s (TCA) 
cycle, and decreased fatigue leads to increased physical activity.  
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Figure 3.10: Proposed schema of peripheral skeletal muscle protein mechanisms reducing 
capability for physical activity in low-active animals.  1: With a decrease in Kreb’s (TCA) cycle 
proteins, there is a decrease in NADH and FADH production, which in turn decrease ATP 
production and physical activity.  2: However, with an increase in the ETC proteins electron 
transfer flavoprotein ubiquinone oxidoreductase and NADH dehydrogenase there is an increase 
in the efficiency of the ETC thereby compensating for the decrease in Kreb’s (TCA) cycle activity.  
3: The structural proteins, radixin, vinculin, vimentin, tubulin beta-3, and alpha tubulin 8 
decrease mobility of actin and thereby reduce force production and physical activity.  
  
 
 
124 
 
IV Lessons Learned from Vivo-morpholinos: How to avoid Vivo-morpholino toxicity 
 
Figure 4.1: Panel A: Mouse that has received Vivo-morpholino treatment and presents with an 
opaque cloudy appearance to the eyes.  Panel B: Dissected Vivo-morpholino treated mouse 
with necrotic tissue in the left ventricle.  
 
Figure 4.2:  MALDI-TOF results of Casq1 Vivo-morpholino at 400 nmol and 2000 nmol 
concentrations (C).  There was no difference between the spectra.  
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Figure 4.3:  Clotting time of whole blood treated with saline, Casq1 Vivo-morpholino, and Vivo-
morpholino cocktail.  Blood treated with Vivo-morpholino cocktail had an increased clotting 
time compared to saline control.  
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Figure 4.4:  Nucleotide base pairing of 5’ and 3’ ends of the Vivo-morpholino treatments.  Bold 
and underline nucleotides indicate location of base pairing.  There was a direct relationship to 
the number of nucleotide base pairs and the number of fatalities.  
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APPENDIX B:  
TABLES 
Table 1:  Soleus differentially expressed proteins between high- and low-active mice.  
Protein Strain 
Expressed 
in 
p Avg 
Ratio 
No. of 
Identified 
Peptides 
% 
Sequence 
Coverage  
QTL 
Calsequestrin 1 C57L/J 0.000025 1.78 2 5 N/A 
Radixin C3H/HeJ 0.00028 1.28 2 3 N/A 
Annexin A6 C57L/J 0.00031 1.53 15 26 Mini 
Muscle
14
 
phosphoenolpyruvate 
carboxykinase 
C3H/HeJ 0.00042 1.5 6 15 N/A 
Peroxiredoxin-6 C3H/HeJ 0.00079 1.46 8 32 N/A 
[Pyruvate dehydrogenase 
[acetyl-transferring]]-
phosphatase 1 
C57L/J 0.0022 1.37 2 4 N/A 
Transferrin C3H/HeJ 0.0026 1.44 12 17 N/A 
Lumican C57L/J 0.004 1.49 3 9 N/A 
Synaptic vesicle membrane 
protein VAT-1 homolog 
C57L/J 0.0046 1.27 3 10 N/A 
Serine protease inhibitor A3K C57L/J 0.005 1.91 6 15 N/A 
Epoxide hydrolase 2 C57L/J 0.0051 1.21 8 13 Duration
12
 
Thioredoxin reducatse 1 C57L/J 0.0051 1.21 3 5 Duration
12
 
myosin, light polypeptide 3 C57L/J 0.0062 1.9 3 14 N/A 
Apolipoprotein A-I C57L/J 0.0062 1.9 3 12 N/A 
Atp5b C3H/HeJ 0.007 1.38 12 31 Speed
12
  
Tubulin beta-3 C3H/HeJ 0.007 1.38 2 12 Duration
12
 
Vimentin C3H/HeJ 0.007 1.38 2 5 N/A 
Hemopexin C3H/HeJ 0.018 1.34 2 4 Distance/D
uration
35
 
Phosphomannomutase 2 C57L/J 0.018 1.31 4 19 N/A 
Hypothetical protein 
Hoch_2831 
C57L/J 0.023 2.09 2 1 N/A 
Annexin A4 C57L/J 0.023 1.16 8 27 N/A 
pyruvate dehydrogenase E1 
component subunit beta 
C57L/J 0.023 1.16 6 18 N/A 
Alpha-2-HS-glycoprotein C3H/HeJ 0.026 1.26 2 24 N/A 
NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 3 
C3H/HeJ 0.027 1.31 4 17 Average 
Speed
183
 
Vinculin C3H/HeJ 0.028 1.23 3 3 Duration
12
 
Tripartite motif-containing 
protein 72  
 
C57L/J 0.029 1.27 7 16 N/A 
Sarcalumenin C57L/J 0.029 1.27 7 15 N/A 
pyruvate dehydrogenase 
protein X component 
C57L/J 0.029 1.27 3 7 N/A 
FK506 binding protein 4 C57L/J 0.029 1.27 2 5 N/A 
Alpha-1 protease inhibitor 2 C3H/HeJ 0.031 1.28 4 21 N/A 
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Protein Strain 
Expressed 
in 
p Avg 
Ratio 
No. of 
Identified 
Peptides 
% 
Sequence 
Coverage  
QTL 
alpha-1-antitrypsin 1-4 C3H/HeJ 0.031 1.28 4 21 N/A 
Serpina1c protein C3H/HeJ 0.031 1.28 7 16 N/A 
Alanyl-tRNA synthase C3H/HeJ 0.031 1.15 8 8 N/A 
ATPase C3H/HeJ 0.031 1.15 7 8 N/A 
Aldehyde dehydrogenase C3H/HeJ 0.031 1.14 5 10 N/A 
6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 1 
C3H/HeJ 0.031 1.14 2 4 N/A 
2-oxoglutarate dehydrogenase C3H/HeJ 0.035 1.16 5 6 Mini-
muscle
14
 
Annexin A5 C3H/HeJ 0.036 1.25 9 29 N/A 
14-3-3 protein gamma subtype C57L/J 0.036 1.2 5 16 N/A 
Ubiquinone biosynthesis 
protein COQ9 
C57L/J 0.042 1.24 4 16 Distance
35
 
Dihydrolipoyllysine-residue 
succinyltransferase component 
of 2-oxoglutarate 
dehydrogenase 
C57L/J 0.22 1.24 5 11 Distance
35
 
       
Protein = Name of the identified protein, strain expressed in = the mouse strain that the 
identified protein was expressed in, p= significance level of differential protein expression as 
obtained from DeCyder, Avg Ratio = derived from the normalized spot volume standardized 
against the intra-gel standard provided by Decyder-software analysis thus providing a measure 
of the magnitude of expression differences between identified proteins, No. of Identified 
Peptides = the number of peptides identified from the picked gel spot, % Sequence Coverage = 
the percentage of the number of amino acids identified in comparison to the total number of 
amino acids in the protein sequence, thus allowing for a confidence interval of 95% that the 
peptide sequence corresponds to the identified protein, QTL = if the identified protein is in a 
Quantitative Trait Loci for a coding gene associated with voluntary physical activity along with 
the literature reference for that QTL.   
 
 
 
 
 
 
 
Table 1. Continued 
 
 
129 
 
Table 2: EDL differentially expressed proteins between high and low-active mice. 
Protein Strain 
Expressed 
in 
p Avg 
Ratio 
No. of 
Identified 
Peptides  
% 
Sequence 
Coverage  
QTL 
v-type proton ATPase 
catalytic subunit A 
C57L/J 0.0016 3.72 2 4 N/A 
Annexin A6 C57L/J 0.0016 2.11 15 24 Mini 
Muscle
14
 
Sdha C3H/HeJ 0.0016 1.43 6 10 N/A 
electron transfer 
flavoprotein-ubiquinone 
oxidoreductase 
C3H/HeJ 0.0016 1.43 3 6 N/A 
Alpha-actinin-2 C3H/HeJ 0.0044 1.82 2 2 Speed
12
 
Apolipoprotein A-I C57L/J 0.0046 2.2 2 7 N/A 
T-complex protein 1 
subunit zeta 
C3H/HeJ 0.035 1.28 4 7 N/A 
Alpha-tubulin 8 C3H/HeJ 0.05 1.45 3 6 Speed
12
 
Protein = Name of the identified protein, Strain expressed in = the mouse strain that the 
identified protein was expressed in, p= significance level of differential protein expression as 
obtained from DeCyder, Avg Ratio = derived from the normalized spot volume standardized 
against the intra-gel standard provided by Decyder-software analysis thus providing a measure 
of the magnitude of expression differences between identified proteins, No. of Identified 
Peptides = the number of peptides identified from the picked gel spot, % Sequence Coverage = 
the percentage of the number of peptides identified in comparison to the total number of 
peptides in the protein sequence indicating that there is a 95% confidence level  that the 
identified protein corresponds to the peptide sequence, QTL = if the identified protein is in a 
Quantitative Trait Loci for a coding gene associated with voluntary physical activity along with 
the literature reference for that QTL.   
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Table 3: Protein expression profiles based on function of the protein 
Protein Strain Over 
Expressed in 
Tissue expressed 
in 
Electron Transport Chain   
Atp5b protein C3H/HeJ Soleus 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 
3 
C3H/HeJ Soleus 
ATPase C3H/HeJ Soleus 
electron transfer flavoprotein ubiquinone 
oxidoreductase 
 
C3H/HeJ Soleus 
   
TCA Cycle    
pyruvate dehydrogenase protein X component C57L/J Soleus 
pyruvate dehydrogenase E1 component subunit beta C57L/J Soleus 
Pyruvate dehydrogenase [acetyl-transferring]-
phosphatase 1 
C57L/J Soleus 
dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex 
C57L/J Soleus 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 
1 
C3H/HeJ Soleus 
phosphomannomutase 2 C57L/J Soleus 
Sdha protein C3H/HeJ EDL 
   
Oxygen Transport    
Transferrin  C3H/HeJ Soleus 
   
Oxidative stress Response    
Hemopexin  C3H/HeJ Soleus 
thioredoxin reducatse 1 C57L/J Soleus 
Peroxiredoxin-6 C3H/HeJ Soleus 
ubiquinone biosynthesis protein COQ9 C57L/J Soleus 
   
Protein Regulation    
Serine protease inhibitor A3K C57L/J Soleus 
alanyl-tRNA Synthase C3H/HeJ Soleus 
FK506 binding protein 4 C57L/J Soleus 
alpha-1 protease inhibitor 2 C3H/HeJ Soleus 
alpha-1-antitrypsin 1-4 precursor 
 
C3H/HeJ Soleus 
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Protein Strain Over 
Expressed in 
Tissue expressed 
in 
Annexin A6 C57L/J Soleus/EDL 
Calsequestrin 1 C57L/J Soleus 
Sarcalumenin C57L/J Soleus 
   
Structural Proteins   
Radixin C3H/HeJ Soleus 
Lumican C57L/J Soleus 
tripartite motif-containing protein 72 C57L/J Soleus 
Vinculin C3H/HeJ Soleus 
Vimentin C3H/HeJ Soleus 
Tubulin beta-3 C3H/HeJ Soleus 
Coflin-2-like C3H/HeJ Soleus 
Alpha-actinin-2 C3H/HeJ EDL 
T-complex protein 1 subunit zeta C3H/HeJ EDL 
Alpha tubulin 8 C3H/HeJ EDL 
   
Other   
Epoxide hydrolase 2 C57L/J Soleus 
aldehyde dehydrogenase C3H/HeJ Soleus 
Hoch 2831 C57L/J Soleus 
apolipoprotein A-I C57L/J Soleus/EDL 
myosin, light polypeptide 3 C57L/J Soleus 
phosphoenolpyruvate carboxykinase C3H/HeJ Soleus 
Serpina1c protein C3H/HeJ Soleus 
synaptic vesicle membrane protein VAT-1 C57L/J Soleus 
14-3-3 protein gamma subtype C57L/J Soleus 
v-type proton ATPase catalytic subunit A C57L/J Soleus 
Annexin A5 C3H/HeJ Soleus 
 
 
 
 
 
 
 
 
Table 3 Continued.  
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Table 4: Co-immunoprecipitation of Annexin VI and Calsequestrin 1 
Identified Protein 
 
Number of Peptides 
 
Percent Sequence covered 
 
Annexin VI   
Soleus C57L/J 
 
  
alpha S1 casein 
 
3 
 
15 
 
   
Soleus C3H/HeJ 
 
  
beta-lactoglobulin 
 
2 
 
8 
 
   
EDL C57L/J 
 
  
alpha S1 casein 
 
3 
 
15 
 
   
EDL C3H/HeJ 
 
  
Actin, alpha 1 
 
2 
 
6 
 
 
   
Calsequestrin 1   
Soleus C57L/J 
 
  
creatine kinase M-type 
 
10 
 
30 
 
alpha S1 casein 
 
3 
 
18 
 
Ldb3 protein 
 
4 
 
19 
 
troponin T3 
 
3 
 
15 
 
desmin 
 
6 
 
12 
 
   
Soleus C3H/HeJ 
 
  
creatine kinase M-type 
 
 
10 
 
30 
 
 
 
133 
 
Identified Protein 
 
 
Number of Peptides 
 
Percent Sequence covered 
 
troponin T3 
 
3 
 
15 
 
Identified proteins from a Co-immunoprecipitation of Annexin A6 and Calsequestrin 1.  Proteins 
were identified by mass spectroscopy and the number of peptides along with the sequence 
percentage is presented.   
  
Table 4 Continued. 
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APPENDIX C: 
 PROTEIN ASSAY TECHNIQUES   
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Protein Extraction - Brain 
1) Make Norris Buffer  
a.  
b. Dissolve PMSF in DMSO and then add to buffer last 
c. Fill to appropriate volume with ultrapure DI water 
d. pH to 7.4 
e. Freeze in 15 ml tubes 
f. See Norris Buffer instructors for further information 
2) Aliquot 300 ul of Norris buffer into the required number of 1.7 ml tubes 
3) Add 30 ul of 10% Tritton X 100 if there is difficulty in viewing proteins.  
4) Put froze brain tissue in buffer solution and using tissue homogenizer grind the tissue 
by pulsing for 10 seconds and resting for 15 seconds.  Continue until tissue is fully 
homogenized avoid excessive foaming. 
a. Cleaning homogenizer with 50/50 Ethanol/water solution and rinse with DI 
water 
5) Put homogenized tissue on ice for 1 hour and vortex every 15 minutes 
6) Centrifuge at 4 degrees C for 30 minutes at max speed 
7) Protein will be in the supernatant 
8) Remove supernatant and put new 0.6 ml tube 
a. Additionally aliquot necessary sample for protein concentration 
9) Place protein in -80.  Move on to protein concentration or store aliquot in -20 for later 
protein concentration 
Protein Extraction – Muscle 
1) Make Dangott Lysis Buffer 
a. 24.6mg CHAPS 
b. 100ul 1M Tris 7.5 
c. 1 complete tablet (Rousch)  
d. 9.9 ml DI water 
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2) If sample is > 100ug aliquot 1000ul of Dangott lysis buffer into 1.7ml tubes.  If it is 
<100ug aliquot 500 ul of buffer 
3) Remove motor and pestle from freezer 
4) Pour liquid nitrogen into motor 
5) Add sample 
6) Grind sample in until fine powder 
7) Using an autoclaved spatula scrap sample into tube with buffer 
8) Let sample sit on ice for 1 hour with vortexing every 15 minutes 
9) Centrifuge for 30 mins at high speed at 4 degrees C 
10) Remove supernatant (protein)   and aliquot into new tubes 
a. Additionally aliquot necessary sample for protein concentration 
11) Place protein in -80.  Move on to protein concentration or store aliquot in -20 for 
later protein concentration 
 
Protein Concentration – Bradford 
Note: for use with Dangott lysis buffer  
1) Using a 96 well plate aliquot 300 ul of coomassie into the necessary number of wells.  
a. Add additional wells for 2000ug/ml BSA standard, 1000 ug/ml BSA standard, 
500 ug/ml, 250 ug/ml standard, and 125 ug/ml standard. 
2) Make dilution series for sample 
a. Typically use Neat, 2x, 4x, 8x, 16x 
b. Combine equal volume of sample with water to achieve dilution (ex: 2x=20ul 
neat and 20 ul water, 4x = 20 ul 2x and 20 ul water) 
3) Add 10 ul of sample, dilutions and standards to the wells containing 300 ul of 
coomassie 
4) Should observe a blue color change 
5) Open the nanodrop program and protein Bradford software 
6) Follow on screen instructions 
a. Add 2ul of each sample to the nanodrop 
7) Clean nanodrop with DI water when done 
 
Protein Concentration – BCA 
Note: for use with Norris buffer 
1) Use 96 well plate and standards as above 
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2) Make dilution series for sample 
a. Typically use Neat, 2x, 4x, 8x, 16x 
b. Combine equal volume of sample with water to achieve dilution (ex: 
2x=20ul neat and 20 ul water, 4x = 20 ul 2x and 20 ul water) 
3) Follow instructions for pierce BCA protein assay kit 
4) For heating place plate on heat block and cover with foil. 
5) Should observe a purple color change 
6) Open the nanodrop program and protein BCA software 
7) Follow on screen instructions 
a. Add 2ul of each sample to the nanodrop 
8) Clean nanodrop with DI water when done 
 
SDS-Page 
A] Preparation of gel plates 
1. Put the glass plates and Aluminum backing plates on a clean surface (like a paper 
towel). 
2. Spray plates with 100% methanol and thoroughly clean with kimwipe.  (PS: they are 
expensive so do not break them!.) 
B] Putting the gel plates on the gel caster unit to create the gel- plate sandwich 
1. Insert the 0.75mm spacers (black ones) on the sides of the plates (1 for each side, so 
2 for 1 pair of plates).   
2. Insert the gel-plates pair in the gel stand vertically with the glass surface facing you. 
  -Make sure all edges are flush or it will leak. 
3. Screw the clamps down on the  plates  
4. Using Gel seal fill the gap between the glass and AL plate 
5. Line the bottom of the red gel holder with parafilm to prevent leaks 
6. Put the grey gel caster in the red gel stand use black cams to lock the caster down  
  -Put binder clamps on the top of the gel plates to prevent leaks 
7. Spray distilled water in the gel – plate surface (in between the 2 plates) to test for 
leaking. 
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C] Preparation of the gel  
Preparation of 12% RUNNING GEL – Muscle  
1. In a small beaker 
-3.3 ml distilled water. 
 -4ml of Acrylamide mix (Bis 30 % acrylamide brown bottle). 
-2.5 ml 1.5M Tris 8.8. 
-100µl of 10% Sodium dodecyl sulfate (SDS). 
-100µl of 10% Ammonium persulfate solution (APS). 
-4 ul of TEMED. 
-MIX WELL 
Preparation of 10% RUNNING GEL-Brain. 
1. In a small beaker 
a. 3.9 ml water 
b. 3.3ml Acyralamide 
c. 2.5 ml 1.5 M Tris 8.8 
d. 100ul 10% SDS 
e. 100ul 10% APS 
f. 4 ul TEMED 
2. Fill gel caster with running gel up to the top of the grey caster 
3. Then fell rest of the caster with water .saturated iso-butanol. 
4. Wait for the gel to harden up.  Takes approximately 15-20 minutes. 
5. After the gel is hardened dump the iso-butanol, and wash 3x with distilled water 
Preparation of STACKING GEL 
Get a small beaker for making the stacking gel. 
-3.4 ml of distilled water.  
- 830 µl of acrylamide mix. 
- 630 µl of Tris 6.8pH. 
-50µl of SDS. 
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-50µl of 10% APS. 
-5 µl of TEMED. 
Fill stacking gel to the top and add combs. Then clamp gels with binder clamps 
D] Sample Preparation  
Note the 0.75 mm spacers on this system can only hold 30ul of sample. Therefore you must 
calculate your sample volume appropriately 
 Example: The lowest protein concentrations for your samples are 1.3ug/ul. You need 
to mix your sample with 4x SDS sample buffer to reach a volume of 30 ul. Therefore 1/4th of 
30 ul is 7.5 ul (the amount of 4x SDS sample buffer you must add for this sample.)  Which 
means you can add 22.5 ul of your sample.  Thereby you will be adding 29.25 ug of protein for 
this sample (22.5*1.3ug/ul). Thus, you must add the same amount of protein for all your 
samples.  So if your next sample has a concentration of 2.5ug/ul.  You would divide 29.25ug 
by 2.5ug/ul telling you that you will add 11.7 ul of that sample to get the same protein 
concentration.  Then you would add 7.5 ul of 4x SDS sample buffer to 11.7 giving you 19.2 ul.  
Fill the remainder to 30 ul (in this case add 10.8ul of water).  REMEMBER LOAD THE SAME 
AMOUNT OF PROTEIN PER SAMPLE AND EACH WELL SHOULD CONTAIN 30 UL OF WATER.  
THIS WILL GIVE A CLEAR RESULT  
1) Once you have added the appropriate amount of sample, 4x SDS buffer and water to 
0.6 ml. Vortex then quick spin the tubes.  Heat the samples at  90 C for 12 minutes.  
Then quick spin the samples. 
a. 200ul Beta mercaptoethanol 
b. 800ul 5x Sample buffer 
i. 150ml water 
ii. 50g glycerol 
iii. 70ml water 
iv. 3.78g Trizma base 
v. pH to 6.8 with HCL 
vi. 30 water 
vii. 10g SDS 
viii. 25ml 0.04% bromophenol blue 
2) Pull the combs from gel casters as slowly as possible.  Wash it with distilled water three 
times.  Clip the gel-plates to the buffer chamber using the red clamps (longer side 
facing you). 
3) Fill the upper and lower buffer chambers with 1x SDS running buffer.  Also, fill the gel 
wells.  Make sure you completely fill the back of the AL plate with buffer 
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a. 900 ml water 
b. 100ml 10x SDS sample buffer 
i. 30.28 g Trizma base 
ii. 144.1gm glycine 
iii. 10gm SDS 
iv. 1000 ml water 
4) Place the well decal on the glass plate, 
5) Disable gel caster and  
6) Add your samples to the wells.  
a. Avoid the outer lanes.  In lane 2 add your maker 
b. Add 30ul of 1x SDS sample buffer to the lanes with no sample 
7) Put the top on the gel chamber matching red to red and black to black.  If running 2 
gels set system to constant volts at 22 mA.  If running 4 gels set to constant volts and 
50 mA.  
8) Let gel run until dye front reaches end of the gel plate DO NOT LET IT RUN OFF 
9) When done disable chamber and remove gels CAREFULLY 
10) Remove stacking gel and cut bottom left corner of gel 
11) Proceed to staining or Western Blotting 
 
Staining-Coomassie 
Note: for use if over 20ug of protein have been load on gel. 
1) Fix gels for 1 hour with Fixative 
a. 100ml Glacial Acetic Acid 
b. 300 ml Ethanol 
c. 600 ml water 
2) Remove from fixative and wash for 1 hour in new fixative 
3) Add Coomassie to properly cover the gel 
4) Wash until bands are blue 
5) Rinse with DI water 
 
Staining – Silver 
For use if less than 20 ug of protein have been load on gel 
1) Fix gels for 1 hour  and then fix in clean fixative for additional hour 
a. 100ml Glacial Acetic Acid  
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b. 300ml Ethanol 
c. 600 ml water 
2) Rise gel in Rinse solution for 20 mins 
a. 200ml ethanol 
b. 800ml water 
3) Rinse gel in water for 10  mins 
4) Soak gel in Sensitizer for 1 min 
a. 200mg sodium thiosulfate 
b. 1000ml water 
5) Rinse gel in water 3 times for 30 seconds 
6) Soak gel in silver nitrate solution for 45 mins (MAKE DEVELOPER) 
a. 2gm silver nitrate 
b. 1000ml water 
7) Rise gel in DI water for 5-10 seconds 
8) Soak gel in developer until bands appear (DO NOT OVER EXPOSE) 
a. 15gm sodiam carbonate 
b. 25 ml Sensitizer 
c. 125ul 37% formaldehyde (add right before developing)  
d. 500 ml water 
9) Soak gel in stop solution for 15 minutes 
a. 50g Tris base 
b. 25 ml glacial acetic acid 
c. 1000ml water 
10) Soak gel in water  
 
Western Blotting 
1) If using a PVDF membrane: Spray methanol on it.  
2) Place gel, membrane, sponges, and filter paper in transfer buffer working solution 
3) .  Rock the membranes and the gel in transfer buffer for 20 minutes. 
4) Assemble the transfer cassette 
a. Black side 
b. Sponge 
c. 2 pieces of filter paper 
d. Gel 
e. Membrane which has been labeled for lane 1 and 10 and the back top left 
portion 
f. 2 pieces of filter paper 
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g. Sponge 
h. White side 
5) using a pipette pressed on the filter paper to remove air bubbles 
6) Place stir bar in transfer tank and turn on when tank is closed 
7) Place cassette in transfer tank with the black side facing the back 
8) Fill with Transfer buffer working solution 
a. 800 ul water 
b. 100 ul Methanol 
c. 100 ul Transfer buffer stock 
i. 1000 ml water 
ii. 22.13 g CAPS 
iii. pH to 11.0 with NaOH 
9) Putt cap on and make sure back matches to black and red matches to red 
10) For muscle run at constant volts and 100mA for 3 hours 
11) For brain  run at constant volts and 100mA for 2 hours and 20 minutes 
12) Remove gel from transfer and block for 1 hour muscle or 40 minutes brain 
a. 500 ul Tween 20 
b. 25 g NFDM 
c. 500m TBS 
13) Make antibody solution and cut plastic bags 
a. The bag will hold 5ml  
b. Mix 5m of blocking buffer with appropriate antibody amount for protein of 
interest 
14) Wash 3x for 5 mins with TBS 
15) Seal membranes in plastic pouch and rock over night in 4 degree C 
16) Next morning remove membranes and wash 3 times for 5 mins in TBS 
17) Add secondary antibody 
a. 5ml blocking buffer 
b. 2.5 ul Secondary Rabbit HRP antibody 
18) Seal pouch and rock for 1 hour at room temp 
19) Wash membrane 3 times for 5 minutes with TBS 
20) Image in Fluckey’s lab (use supersensitivity setting if weak signal) 
a. Use Pierce HRP kit 
i. 7ml brown bottle and 7 ml white bottle 
ii. Image for 5 mins on setting 1 for the flurochem 
1. Use plastic sheet to cover membrane while in imager 
Chloroform Methanol Precipitation 
If you have too low of a protein concentration you can concentrate your sample with this.  
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1) Remove enough volume of each sample to equal your desired protein concentration. 
Note the protein content of the volume you remove must be the same 
2) Place volume in 1.7ml tube 
3) Add 600ul MeOH 
4) Vortex 
5) Add 150 ul Chloroform 
6) Vortex 
7) Add 450 ul water 
8) Spin at high speed for 1 min 
9) Protein at interface 
10) Remove upper layer 
11) Add 450 ul MeOH 
12) Vortex 
13) Spin at high for 2 mins 
14) Proteins in Pellet 
15) Remove supernatant  
16) Wash pellet with 500 ul of MeOH 
17) Vortex 
18) Spin for 1 min 
19) Remove MeOH 
20) Air dry pellet for 5 mins 
21) If you are going to use this sample on 2 gels add 30 ul 2x sample buffer and 30 ul of 
water 
a. Adjust for larger number of gels 
22) Vortex until pellet dissolves 
23) Freeze at -20 or load on gel 
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APPENDIX D: 
 VIVO-MORPHOLINO DOSE CALCULATOR  
Mass per injection (mg) = [Dose per injection (mg/kg) * Animal mass (g)] / 1000 
Nanomoles per injection= [Mass per injection (mg) / 1000] / [*Est. Formula (mass g/mole)^9] 
Vol per injection at 0.5 mM (ul) = (Nanomoles per injection * 10^9) / (0.0005 * 10^6) 
*Note estimated formula mass is established by GeneTools as 10000 g/mole 
 
